
VA versus Non-VA Quality of Care: A Living Systematic Review

Updated June 2024

VA



U.S. Department of Veterans Affairs

Veterans Health Administration
Health Systems Research

Recommended citation: Shekelle P, Maggard-Gibbons M, Blegen M, et al. VA versus Non-VA Quality of Care: A Living Systematic Review. Washington, DC: Evidence Synthesis Program, Health Systems Research, Office of Research and Development, Department of Veterans Affairs. VA ESP Project #05-226; 2024.

Appendix

SEARCH STRATEGIES

	Search Statement	Results
PubMed	<p>"United States Department of Veterans Affairs"[mh] OR "Veterans Health"[mh] OR "veterans health services"[mh] OR "Hospitals, Veterans"[mh] OR "veterans affairs"[tiab] OR "veterans health"[tiab] OR "veterans choice"[tiab]</p> <p>AND</p> <p>Compar*[ti] OR "vs"[ti] OR versus[ti] OR difference[ti] OR "dually enrolled"[tiab] OR "dual system*"[tiab] OR "dual enrollment"[tiab] OR "overlapping use"[tiab] OR (examine*[tiab] AND (access*[tiab] OR availab*[tiab])) OR (("community care*"[tiab] OR "Community Health Services"[Majr] AND impact*[tiab]) OR ((other[tiab] OR "private sector"[tiab] OR "non-VA"[tiab] OR medicare[tiab] OR "commercially managed"[tiab] OR "non veteran*"[tiab] OR "non VAMC"[tiab] OR "non va"[tiab] OR "non federal hospital*"[tiab] OR "university hospital*"[tiab] OR nonveteran*[tiab] OR "nonfederal hospital*"[tiab]) AND (compar*[tiab] OR comparative study[pt]))</p>	
	1 1/1/2015–3/9/2023	2200
	2 3/1/2023–10/6/2023	224
	3 10/1/2023–5/9/2024	238
PsycInfo	<p>TI("Veterans Health" OR "veterans affairs" OR "veterans health" OR "veterans choice") OR AB("Veterans Health" OR "veterans affairs" OR "veterans health" OR "veterans choice")</p> <p>AND</p> <p>TI(Compar* OR "vs" OR versus OR difference) OR (TI("dually enrolled" OR "dual system*" OR "dual enrollment" OR "overlapping use") OR AB("dually enrolled" OR "dual system*" OR "dual enrollment" OR "overlapping use")) OR (TI(examine*) AND TI(access* OR availab*)) OR (TI(examine*) AND AB(access* OR availab*)) OR (AB(examine*) AND TI(access* OR availab*)) OR (AB(examine*) AND AB(access* OR availab*)) OR ((TI("community care*") OR AB("community care*") OR MM("Community Mental Health Services")) AND (TI(impact* OR AB(impact*))) OR (TI(other OR "private sector" OR "non-VA" OR medicare OR "commercially managed" OR "non veteran*" OR "non VAMC" OR "non va" OR "non federal hospital*" OR "university hospital*" OR nonveteran* OR "nonfederal hospital*") OR AB(other OR "private sector" OR "non-VA" OR medicare OR "commercially managed" OR "non veteran*" OR "non VAMC" OR "non va" OR "non federal hospital*" OR</p>	



	"university hospital*" OR nonveteran* OR "nonfederal hospital*") AND (TI(compar*) OR AB(compar*) OR TI("comparative study"))	
1	1/1/2015–3/10/2023	112
2	3/1/2023–10/6/2023	3
3	10/1/2023–5/9/2024	7
Web of Science	<p>TI=("veterans affairs" OR "veterans health" OR "veterans choice" OR "veterans hospital") OR AB=("veterans affairs" OR "veterans health" OR "veterans choice" OR "veterans hospital")</p> <p>AND</p> <p>TI=(compar* OR "vs" OR versus OR difference) OR TI=("dually enrolled" OR "dual system*" OR "dual enrollment" OR "overlapping use") OR AB=("dually enrolled" OR "dual system*" OR "dual enrollment" OR "overlapping use") OR ((TI=(examine*) OR AB=(examine*)) AND (TI=(access* OR availab*) OR AB=(access* OR availab*))) OR ((TI=("community care*") OR AB=("community care*")) AND (TI=(impact*) OR AB=(impact*))) OR (TI=(other OR "private sector" OR "non-VA" OR medicare OR "commercially managed" OR "non veteran*" OR "non VAMC" OR "non va" OR "non federal hospital*" OR "university hospital*" OR nonveteran* OR "nonfederal hospital*") OR AB=(other OR "private sector" OR "non-VA" OR medicare OR "commercially managed" OR "non veteran*" OR "non VAMC" OR "non va" OR "non federal hospital*" OR "university hospital*" OR nonveteran* OR "nonfederal hospital*")) AND (TI=(compar*) OR AB=(compar*))</p>	
1	1/1/2015–3/15/2023	136
2	3/1/2023–10/6/2023	17
3	10/1/2023–5/9/2024	158
	Total	3,095
	Total after deduplication	2,800

STUDIES WITH UNREPRESENTATIVE SAMPLES OR COMPARISONS

Citation

Bartel, M. J., D. J. Robertson and H. Pohl (2016). "Colonoscopy practice for veterans within and outside the Veterans Affairs setting: a matched cohort study." *Gastrointest Endosc* 84(2): 272-278.

Chao, D., H. Buddha, C. Damodaran, L. Tran, R. Strong and C. S. Jackson (2020). "Outcomes Comparison of the Veterans' Choice Program With the Veterans Affairs Health Care System for Hepatitis C Treatment." *Fed Pract* 37(Suppl 3): S18-s24.

Cullen, S. W., M. Xie, J. M. Vermeulen and S. C. Marcus (2019). "Comparing Rates of Adverse Events and Medical Errors on Inpatient Psychiatric Units at Veterans Health Administration and Community-based General Hospitals." *Med Care* 57(11): 913-920.

Dizon, M.P., et al., Comparing the Quality of Ambulatory Surgical Care for Skin Cancer in a Veterans Affairs Clinic and a Fee-For-Service Practice Using Clinical and Patient-Reported Measures. *PLoS One*, 2017. 12(1): p. e0171253.

Dueker, J. M. and A. Khalid (2020). "Performance of the Veterans Choice Program for Improving Access to Colonoscopy at a Tertiary VA Facility." *Fed Pract* 37(5): 224-228.

Geraci, T., et al., Lobectomy for Lung Cancer at Veterans Administration Medical Center Versus Academic Medical Center. *Ann Thorac Surg*, 2017. 103(6): p. 1715-1722.

Grubbs, K. M., J. C. Fortney, J. Pyne, D. Mittal, J. Ray and T. J. Hudson (2018). "A Comparison of Collaborative Care Outcomes in Two Health Care Systems: VA Clinics and Federally Qualified Health Centers." *Psychiatr Serv* 69(4): 431-437.

STUDIES EXCLUDED DURING FULL-TEXT SCREENING

NON-SURGICAL CARE

Ineligible Comparison, N = 58

1. Augustine, M.R., et al., Reasons Older Veterans Use the Veterans Health Administration and Non-VHA Care in an Urban Environment. *J Am Board Fam Med*, 2021. 34(2): p. 291-300.
2. Benzer, J.K., et al., Survey of Patient-Centered Coordination of Care for Diabetes with Cardiovascular and Mental Health Comorbidities in the Department of Veterans Affairs. *Journal of General Internal Medicine*, 2019. 34(1): p. 43-49.
3. Bouldin, E.D., et al., Medicare-VHA dual use is associated with poorer chronic wound healing. *Wound Repair Regen*, 2016. 24(5): p. 913-922.
4. Burke, J.F. and B.C. Callaghan, Author response: Neuroimaging overuse is more common in Medicare compared with the VA. *Neurology*, 2017. 88(6): p. 608.
5. Chen, V.W., et al., Case Sampling vs Universal Review for Evaluating Hospital Postoperative Mortality in US Surgical Quality Improvement Programs. *JAMA Surg*, 2023.
6. Dayoub, E.J., et al., Federal Payments for Coronary Revascularization Procedures Among Dual Enrollees in Medicare Advantage and the Veterans Affairs Health Care System. *JAMA Netw Open*, 2020. 3(4): p. e201451.
7. Desmarais, J. and C.Q. Chu, Utility of Anakinra in Acute Crystalline Diseases: A Retrospective Study Comparing a University Hospital with a Veterans Affairs Medical Center. *J Rheumatol*, 2019. 46(7): p. 748-750.
8. Ebrahimi, R., et al., Trends in Cardiovascular Disease Mortality in US Women Veterans vs Civilians. *JAMA Netw Open*, 2023. 6(10): p. e2340242.
9. Feyman, Y., A. Legler, and K.N. Griffith, Appointment wait time data for primary & specialty care in veterans health administration facilities vs. community medical centers. *Data Brief*, 2021. 36: p. 107134.
10. Gidwani-Marszowski, R., et al., Quality Of End-Of-Life Care Is Higher In The VA Compared To Care Paid For By Traditional Medicare. *Health Aff (Millwood)*, 2018. 37(1): p. 95-103.
11. Govier, D.J., et al., Early Impact of VA MISSION Act Implementation on Primary Care Appointment Wait Time. *J Gen Intern Med*, 2023. 38(4): p. 889-897.
12. Griebing, T.L., Re: Comparing Catheter-Associated Urinary Tract Infection Prevention Programs between Veterans Affairs Nursing Homes and Non-Veterans Affairs Nursing Homes. *J Urol*, 2018. 200(6): p. 1142.
13. Hebert, P.L., et al., Reliance on Medicare Providers by Veterans after Becoming Age-Eligible for Medicare is Associated with the Use of More Outpatient Services. *Health Serv Res*, 2018. 53 Suppl 3(Suppl 3): p. 5159-5180.
14. Johnston, J.C. and T.P. Sartwelle, Letter re: Neuroimaging overuse is more common in Medicare compared with the VA. *Neurology*, 2017. 88(6): p. 608.
15. Jones, A.L., et al., National Media Coverage of the Veterans Affairs Waitlist Scandal: Effects on Veterans' Distrust of the VA Health Care System. *Med Care*, 2021. 59(Suppl 3): p. S322-S326.
16. Klyce, D.W., et al., Suicide Attempts and Ideation Among Veterans/Service Members and Non-Veterans Over 5 Years Following Traumatic Brain Injury: A Combined NIDILRR and VA TBI Model Systems Study. *J Head Trauma Rehabil*, 2023.

17. Leonard, C., et al., Operationalizing an Implementation Framework to Disseminate a Care Coordination Program for Rural Veterans. *Journal of General Internal Medicine*, 2019. 34(1): p. 58-66.
18. Lewinski, A.A., et al., Applied Rapid Qualitative Analysis to Develop a Contextually Appropriate Intervention and Increase the Likelihood of Uptake. *Med Care*, 2021. 59(Suppl 3): p. S242-S251.
19. Loganathan, S.K., et al., Racial and Ethnic Differences in Satisfaction with Care Coordination Among VA and non-VA Medicare Beneficiaries. *Health Equity*, 2017. 1(1): p. 50-60.
20. Machlin, S.R. and P. Muhuri, Characteristics and Health Care Expenditures of VA Health System Users versus Other Veterans, 2014-2015 (Combined), in *Statistical Brief (Medical Expenditure Panel Survey (US))*. 2001, Agency for Healthcare Research and Quality (US): Rockville (MD).
21. Malhotra, A., M. Vaughan-Sarrazin, and G.E. Rosenthal, Elderly veterans with dual eligibility for VA and Medicare services: where do they obtain a colonoscopy? *Am J Manag Care*, 2015. 21(4): p. e264-70.
22. Mattocks, K.M., et al., Understanding Maternity Care Coordination for Women Veterans Using an Integrated Care Model Approach. *Journal of General Internal Medicine*, 2019. 34(1): p. 50-57.
23. McAlpine, K., et al., Surgeon-level versus hospital-level quality variance in kidney cancer surgery. *Urol Oncol*, 2023. 41(5): p. 257.e7-257.e17.
24. McCreight, M.S., et al., Practical Use of Process Mapping to Guide Implementation of a Care Coordination Program for Rural Veterans. *Journal of General Internal Medicine*, 2019. 34(1): p. 67-74.
25. Mohr, D.C., et al., Organizational Coordination and Patient Experiences of Specialty Care Integration. *Journal of General Internal Medicine*, 2019. 34(1): p. 30-36.
26. Morral, A.R., T.L. Schell, and R. Smart, Comparison of Suicide Rates Among US Veteran and Nonveteran Populations. *JAMA Netw Open*, 2023. 6(7): p. e2324191.
27. Mudumbai, S.C., et al., Perioperative Opioid Prescribing Patterns and Readmissions After Total Knee Arthroplasty in a National Cohort of Veterans Health Administration Patients. *Pain Med*, 2020. 21(3): p. 595-603.
28. Nadpara, P.A., et al., Risk Factors for Serious Prescription Opioid-Induced Respiratory Depression or Overdose: Comparison of Commercially Insured and Veterans Health Affairs Populations. *Pain Med*, 2018. 19(1): p. 79-96.
29. Nelson, R.E., et al., The Impact of a Change in the Price of VA Health Care on Utilization of VA and Medicare Services. *Med Care*, 2018. 56(7): p. 569-576.
30. Nelson, R.E., et al., Costs Associated with Health Care Services Accessed through VA and in the Community through Medicare for Veterans Experiencing Homelessness. *Health Serv Res*, 2018. 53 Suppl 3(Suppl Suppl 3): p. 5352-5374.
31. New, M.L., et al., Differences in VA and Non-VA Pulmonary Nodules: All Evaluations Are not Created Equal. *Clin Lung Cancer*, 2023. 24(5): p. 407-414.
32. Noël, P.H., et al., Patient experience of health care system hassles: Dual-system vs single-system users. *Health Serv Res*, 2020. 55(4): p. 548-555.
33. Nuti, S.V., L. Qin, and H.M. Krumholz, Outcome After Admission at Veterans Affairs vs Non-Veterans Affairs Hospitals--Reply. *Jama*, 2016. 316(3): p. 346.
34. O'Hanlon, C.E., C. Farmer, and C. Gidengil, Comparing VA to Non-VA Care. *J Gen Intern Med*, 2017. 32(2): p. 152.



35. Olmos-Ochoa, T.T., et al., Staff Perspectives on Primary Care Teams as De Facto “Hubs” for Care Coordination in VA: a Qualitative Study. *Journal of General Internal Medicine*, 2019. 34(1): p. 82-89.
36. Pershing, S., et al., Treating age-related macular degeneration: comparing the use of two drugs among medicare and veterans affairs populations. *Health Aff (Millwood)*, 2015. 34(2): p. 229-38.
37. Peterson, K., et al., Health Care Coordination Theoretical Frameworks: a Systematic Scoping Review to Increase Their Understanding and Use in Practice. *Journal of General Internal Medicine*, 2019. 34(1): p. 90-98.
38. Radomski, T.R., M.J. Fine, and W.F. Gellad, Outcome After Admission at Veterans Affairs vs Non-Veterans Affairs Hospitals. *Jama*, 2016. 316(3): p. 345-6.
39. Radomski, T.R., et al., The Impact of Medication-Based Risk Adjustment on the Association Between Veteran Health Outcomes and Dual Health System Use. *J Gen Intern Med*, 2017. 32(9): p. 967-973.
40. Ramkumar, M. and S.T. Crowley, Kidney Transplantation Rates of Veterans Administration-Listed Patients Compared with Rates of Patients on Nonveteran Lists. *J Am Soc Nephrol*, 2018. 29(10): p. 2449-2450.
41. Rinne, S.T., et al., VA Provider Perspectives on Coordinating COPD Care Across Health Systems. *Journal of General Internal Medicine*, 2019. 34(1): p. 37-42.
42. Rose, D.E., et al., Variations in VA and Medicare Use Among Veterans With Diabetes: Impacts on Ambulatory Care Sensitive Conditions Hospitalizations for 2008, 2009, and 2010. *Med Care*, 2019. 57(6): p. 425-436.
43. Rose, L., et al., Association of Expanded Health Care Networks With Utilization Among Veterans Affairs Enrollees. *JAMA Netw Open*, 2021. 4(10): p. e2131141.
44. Rosenberg, K., End-Of-Life Cancer Care For Veterans Through The VA Vs. Medicare. *Am J Nurs*, 2018. 118(5): p. 70.
45. Trivedi, A.N., et al., Dual Use and Hospital Admissions among Veterans Enrolled in the VA's Homeless Patient Aligned Care Team. *Health Serv Res*, 2018. 53 Suppl 3(Suppl Suppl 3): p. 5219-5237.
46. Trivedi, A.N., et al., Agreement Between HEDIS Performance Assessments in the VA and Medicare Advantage: Is Quality in the Eye of the Beholder? *Inquiry*, 2016. 53.
47. Tummalapalli, S.L. and S. Keyhani, Trends in Preventative Health Services for Veterans with Military Coverage Compared to Non-Military Coverage. *J Gen Intern Med*, 2020. 35(4): p. 1330-1333.
48. Valle, J.A., et al., Dual antiplatelet therapy in non-ST elevation acute coronary syndromes at Veterans Affairs Hospitals. *Heart*, 2019. 105(20): p. 1575-1582.
49. Veet, C.A., et al., Impact of Healthcare Delivery System Type on Clinical, Utilization, and Cost Outcomes of Patient-Centered Medical Homes: a Systematic Review. *J Gen Intern Med*, 2020. 35(4): p. 1276-1284.
50. Ward, R., et al., An Evaluation of Statin Use Among Patients with Type 2 Diabetes at High Risk of Cardiovascular Events Across Multiple Health Care Systems. *J Manag Care Spec Pharm*, 2020. 26(9): p. 1090-1098.
51. Weeks, W.B., Comparing VA to Non-VA Care. *J Gen Intern Med*, 2017. 32(2): p. 150-151.
52. Weinberger, D.M., et al., Excess Mortality Among Patients in the Veterans Affairs Health System Compared With the Overall US Population During the First Year of the COVID-19 Pandemic. *JAMA Netw Open*, 2023. 6(5): p. e2312140.



53. Wong, E.S., et al., Impact of VHA's primary care intensive management program on dual system use. *Healthc (Amst)*, 2020. 8(3): p. 100450.
54. Wray, C.M., M. Khare, and S. Keyhani, Access to Care, Cost of Care, and Satisfaction With Care Among Adults With Private and Public Health Insurance in the US. *JAMA Netw Open*, 2021. 4(6): p. e2110275.
55. Wray, C.M., L. Lopez, and S. Keyhani, "Comparing VA and Non-VA Care Quality". *J Gen Intern Med*, 2019. 34(4): p. 485.
56. Yoon, J., et al., Use of the Veterans' Choice Program and Attrition From Veterans Health Administration Primary Care. *Med Care*, 2020. 58(12): p. 1091-1097.
57. Yu, M.K., et al., Trends in Timing of Dialysis Initiation within Versus Outside the Department of Veterans Affairs. *Clin J Am Soc Nephrol*, 2015. 10(8): p. 1418-27.
58. Zulman, D.M., et al., Effects of Intensive Primary Care on High-Need Patient Experiences: Survey Findings from a Veterans Affairs Randomized Quality Improvement Trial. *Journal of General Internal Medicine*, 2019. 34(1): p. 75-81.

Ineligible Outcome, N = 3

1. Dismuke-Greer, C.E., et al., Economic impact of comorbid TBI-dementia on VA facility and non-VA facility costs, 2000-2020. *Brain Inj*, 2022. 36(5): p. 673-682.
2. Wray, C., et al., Digital Health Skillsets and Digital Preparedness: Comparison of Veterans Health Administration Users and Other Veterans Nationally. *JMIR Form Res*, 2022. 6(1): p. e32764.
3. Scruggs-Wodkowski, E., et al., Comparing practices to prevent infectious diseases transmission among Veterans Affairs and Nonveterans Affairs hospitals: Results from a national survey in the United States. *Am J Infect Control*, 2024. 52(4): p. 495-497.

Ineligible Setting (Surgery), N = 8

1. Billig, J.I., et al., The Impact of Community Care Referral on Time to Surgery for Veterans With Carpal Tunnel Syndrome. *Med Care*, 2021. 59(Suppl 3): p. S279-S285.
2. Buys, M.J., et al., Postsurgical opioid prescribing among veterans using community care for orthopedic surgery at non-VA hospitals compared to a VA hospital with a transitional pain service: a retrospective cohort study. *Reg Anesth Pain Med*, 2024.
3. George, E.L., et al., Comparing Veterans Affairs and Private Sector Perioperative Outcomes After Noncardiac Surgery. *JAMA Surg*, 2021.
4. George, E.L., et al., Outcomes of Women Undergoing Noncardiac Surgery in Veterans Affairs Compared With Non-Veterans Affairs Care Settings. *JAMA Surg*, 2024. 159(5): p. 501-509.
5. Harris, A.H.S., et al., Comparing Complication Rates After Elective Total Knee Arthroplasty Delivered Or Purchased By The VA. *Health Aff (Millwood)*, 2021. 40(8): p. 1312-1320.
6. Pettey, W.B.P., et al., Comparing Driving Miles for Department of Veterans Affairs-delivered Versus Department of Veterans Affairs-purchased Cataract Surgery. *Med Care*, 2021. 59(Suppl 3): p. S307-S313.
7. Rosen, A. K., E. E. Beilstein-Wedel, A. H. S. Harris, M. Shwartz, M. E. Vanneman, T. H. Wagner and N. J. Giori (2022). "Comparing Postoperative Readmission Rates Between Veterans Receiving Total Knee Arthroplasty in the Veterans Health Administration Versus Community Care." *Med Care* 60(2): 178-186.
8. Simmonds, A., et al., Comparing Outcomes in Patients Undergoing Colectomy at Veteran Affairs Hospitals and Non-Veteran Affairs Hospitals: A Multiinstitutional Study. *J Surg Res*, 2024. 295: p. 449-456.



Ineligible Publication Type, N = 6

1. Garvin, L.A., et al., Interorganizational Care Coordination of Rural Veterans by Veterans Affairs and Community Care Programs: A Systematic Review. *Med Care*, 2021. 59(Suppl 3): p. S259-S269.
2. Gordon, S.H., et al., County-level Predictors of Growth in Community-based Primary Care Use Among Veterans. *Med Care*, 2021. 59(Suppl 3): p. S301-S306.
3. Greenstone, C.L., et al., Standardizing Care Coordination Within the Department of Veterans Affairs. *Journal of General Internal Medicine*, 2019. 34(1): p. 4-6.
4. Hynes, D.M., et al., Veterans' Use of Veterans Health Administration Primary Care in an Era of Expanding Choice. *Med Care*, 2021. 59(Suppl 3): p. S292-S300.
5. Mattocks, K.M., et al., Understanding VA's Use of and Relationships With Community Care Providers Under the MISSION Act. *Med Care*, 2021. 59(Suppl 3): p. S252-S258.
6. Vashi, A.A., et al., Community Urgent Care Use Following Implementation of the Veterans Affairs Maintaining Internal Systems and Strengthening Integrated Outside Networks Act. *Med Care*, 2021. 59(Suppl 3): p. S314-S321.

Ineligible Design (Non-Research or Qualitative Study), N = 8

1. Cordasco, K.M., et al., Coordinating Care Across VA Providers and Settings: Policy and Research Recommendations from VA's State of the Art Conference. *Journal of General Internal Medicine*, 2019. 34(1): p. 11-17.
2. Cordasco, K.M., et al., Improving Care Coordination for Veterans Within VA and Across Healthcare Systems. *Journal of General Internal Medicine*, 2019. 34(1): p. 1-3.
3. Gittell, J.H. and L. Hajjar, Strengthening Patient-Centered Care in the VHA: A Relational Model of Change. *Journal of General Internal Medicine*, 2019. 34(1): p. 7-10.
4. Lafferty, M., D. J. Govier, S. E. Golden, N. G. Disher, D. M. Hynes and C. G. Slatore (2023). "VA-Delivered or VA-Purchased Care: Important Factors for Veterans Navigating Care Decisions." *J Gen Intern Med* 38(7): 1647-1654.
5. Mattocks, K.M., et al., Recommendations for the Evaluation of Cross-System Care Coordination from the VA State-of-the-art Working Group on VA/Non-VA Care. *Journal of General Internal Medicine*, 2019. 34(1): p. 18-23.
6. Mattocks, K.M., et al., Innovations in Community Care Programs, Policies, and Research. *Med Care*, 2021. 59(Suppl 3): p. S229-S231.
7. McDonald, K.M., et al., Incorporating Theory into Practice: Reconceptualizing Exemplary Care Coordination Initiatives from the US Veterans Health Delivery System. *Journal of General Internal Medicine*, 2019. 34(1): p. 24-29.
8. Mengeling, M.A., et al., Partnership Forum: The Role of Research in the Transformation of Veterans Affairs Community Care. *Med Care*, 2021. 59(Suppl 3): p. S232-S241.

Unrepresentative Sample or Comparison, N = 5

1. Bartel, M.J., D.J. Robertson, and H. Pohl, Colonoscopy practice for veterans within and outside the Veterans Affairs setting: a matched cohort study. *Gastrointest Endosc*, 2016. 84(2): p. 272-8.
2. Chao, D., et al., Outcomes Comparison of the Veterans' Choice Program With the Veterans Affairs Health Care System for Hepatitis C Treatment. *Fed Pract*, 2020. 37(Suppl 3): p. S18-s24.

3. Cullen, S.W., et al., Comparing Rates of Adverse Events and Medical Errors on Inpatient Psychiatric Units at Veterans Health Administration and Community-based General Hospitals. *Med Care*, 2019. 57(11): p. 913-920.
4. Dueker, J.M. and A. Khalid, Performance of the Veterans Choice Program for Improving Access to Colonoscopy at a Tertiary VA Facility. *Fed Pract*, 2020. 37(5): p. 224-228.
5. Grubbs, K.M., et al., A Comparison of Collaborative Care Outcomes in Two Health Care Systems: VA Clinics and Federally Qualified Health Centers. *Psychiatr Serv*, 2018. 69(4): p. 431-437.



SURGICAL CARE

Ineligible Comparison, N = 19

1. Benzer, J.K., et al., Survey of Patient-Centered Coordination of Care for Diabetes with Cardiovascular and Mental Health Comorbidities in the Department of Veterans Affairs. *Journal of General Internal Medicine*, 2019. 34(1): p. 43-49.
2. Billig, J.I., et al., Surgical Timing for Carpal Tunnel Syndrome: A Comparison of Health Care Delivery in the Veterans Administration and Private Sector. *J Hand Surg Am*, 2021. 46(7): p. 544-551.
3. Clarke, E.L., et al., Association of Tumor Characteristics With Insurance Type Among Patients Undergoing Mohs Micrographic Surgery for Nonmelanoma Skin Cancer. *JAMA Dermatol*, 2022. 158(8): p. 919-922.
4. Dayoub, E.J., et al., Federal Payments for Coronary Revascularization Procedures Among Dual Enrollees in Medicare Advantage and the Veterans Affairs Health Care System. *JAMA Netw Open*, 2020. 3(4): p. e201451.
5. Jones, A.L., et al., National Media Coverage of the Veterans Affairs Waitlist Scandal: Effects on Veterans' Distrust of the VA Health Care System. *Med Care*, 2021. 59(Suppl 3): p. S322-S326.
6. Leonard, C., et al., Operationalizing an Implementation Framework to Disseminate a Care Coordination Program for Rural Veterans. *Journal of General Internal Medicine*, 2019. 34(1): p. 58-66.
7. Lewinski, A.A., et al., Applied Rapid Qualitative Analysis to Develop a Contextually Appropriate Intervention and Increase the Likelihood of Uptake. *Med Care*, 2021. 59(Suppl 3): p. S242-S251.
8. Mattocks, K.M., et al., Understanding Maternity Care Coordination for Women Veterans Using an Integrated Care Model Approach. *Journal of General Internal Medicine*, 2019. 34(1): p. 50-57.
9. McCreight, M.S., et al., Practical Use of Process Mapping to Guide Implementation of a Care Coordination Program for Rural Veterans. *Journal of General Internal Medicine*, 2019. 34(1): p. 67-74.
10. Mohr, D.C., et al., Organizational Coordination and Patient Experiences of Specialty Care Integration. *Journal of General Internal Medicine*, 2019. 34(1): p. 30-36.
11. Mudumbai, S.C., et al., Perioperative Opioid Prescribing Patterns and Readmissions After Total Knee Arthroplasty in a National Cohort of Veterans Health Administration Patients. *Pain Med*, 2020. 21(3): p. 595-603.
12. Mull, H.J., et al., Emergency Department Use After Outpatient Surgery Among Dually Enrolled VA and Medicare Patients. *Qual Manag Health Care*, 2019. 28(4): p. 191-199.
13. Napolitano, M.A., et al., Direct Comparison of Outcomes After Transcatheter Aortic Valve Replacement in Veterans and Non-Veterans Using the Transcatheter Valve Therapy Registry. *J Invasive Cardiol*, 2022. 34(8): p. E601-e610.
14. Olmos-Ochoa, T.T., et al., Staff Perspectives on Primary Care Teams as De Facto "Hubs" for Care Coordination in VA: a Qualitative Study. *Journal of General Internal Medicine*, 2019. 34(1): p. 82-89.
15. Peterson, K., et al., Health Care Coordination Theoretical Frameworks: a Systematic Scoping Review to Increase Their Understanding and Use in Practice. *Journal of General Internal Medicine*, 2019. 34(1): p. 90-98.



16. Rinne, S.T., et al., VA Provider Perspectives on Coordinating COPD Care Across Health Systems. *Journal of General Internal Medicine*, 2019. 34(1): p. 37-42.
17. Shih, L., et al., The Impact of Hospital-Based Systems on Plastic Surgery Resident Education: Veterans Affairs Medical Centers versus Public County Hospitals. *Plast Reconstr Surg*, 2020. 146(5): p. 707e-708e.
18. Valle, J.A., et al., Dual antiplatelet therapy in non-ST elevation acute coronary syndromes at Veterans Affairs Hospitals. *Heart*, 2019. 105(20): p. 1575-1582.
19. Zulman, D.M., et al., Effects of Intensive Primary Care on High-Need Patient Experiences: Survey Findings from a Veterans Affairs Randomized Quality Improvement Trial. *Journal of General Internal Medicine*, 2019. 34(1): p. 75-81.

Ineligible Setting (Non-Surgery), N = 19

1. Carico, R., et al., Receipt of Overlapping Opioid and Benzodiazepine Prescriptions Among Veterans Dually Enrolled in Medicare Part D and the Department of Veterans Affairs: A Cross-sectional Study. *Ann Intern Med*, 2018. 169(9): p. 593-601.
2. Cashion, W., et al., Source of Post-Transplant Care and Mortality among Kidney Transplant Recipients Dually Enrolled in VA and Medicare. *Clin J Am Soc Nephrol*, 2021. 16(3): p. 437-445.
3. Chan, D.C., et al., Mortality among US veterans after emergency visits to Veterans Affairs and other hospitals: retrospective cohort study. *BMJ*, 2022. 376: p. e068099.
4. Davila, H., et al., Rural Veterans' Experiences With Outpatient Care in the Veterans Health Administration Versus Community Care. *Med Care*, 2021. 59(Suppl 3): p. S286-S291.
5. Ebrahimi, R., et al., Trends in Cardiovascular Disease Mortality in US Women Veterans vs Civilians. *JAMA Netw Open*, 2023. 6(10): p. e2340242.
6. Feyman, Y., D.A. Asfaw, and K.N. Griffith, Geographic Variation in Appointment Wait Times for US Military Veterans. *JAMA Netw Open*, 2022. 5(8): p. e2228783.
7. Florez, H.J., et al., Differences in complications, cardiovascular risk factor, and diabetes management among participants enrolled at veterans affairs (VA) and non-VA medical centers in the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE). *Diabetes Res Clin Pract*, 2021. 184: p. 109188.
8. Griebling, T.L., Re: Comparing Catheter-Associated Urinary Tract Infection Prevention Programs between Veterans Affairs Nursing Homes and Non-Veterans Affairs Nursing Homes. *J Urol*, 2018. 200(6): p. 1142.
9. Gurewich, D., et al., Did Access to Care Improve Since Passage of the Veterans Choice Act?: Differences Between Rural and Urban Veterans. *Med Care*, 2021. 59(Suppl 3): p. S270-S278.
10. LaBedz, S.L., et al., Chronic Obstructive Pulmonary Disease Outcomes at Veterans Affairs Versus Non-Veterans Affairs Hospitals. *Chronic Obstr Pulm Dis*, 2021. 8(3): p. 306-313.
11. Moyo, P., et al., Dual Receipt of Prescription Opioids From the Department of Veterans Affairs and Medicare Part D and Prescription Opioid Overdose Death Among Veterans: A Nested Case-Control Study. *Ann Intern Med*, 2019. 170(7): p. 433-442.
12. Nuti, S.V., et al., Association of Admission to Veterans Affairs Hospitals vs Non-Veterans Affairs Hospitals With Mortality and Readmission Rates Among Older Men Hospitalized With Acute Myocardial Infarction, Heart Failure, or Pneumonia. *JAMA*, 2016. 315(6): p. 582-92.
13. Rose, L., et al., Association of Expanded Health Care Networks With Utilization Among Veterans Affairs Enrollees. *JAMA Netw Open*, 2021. 4(10): p. e2131141.
14. Schuttner, L., et al., Factors Associated With Low-Value Cancer Screenings in the Veterans Health Administration. *JAMA Netw Open*, 2021. 4(10): p. e2130581.



15. Scruggs-Wodkowski, E., et al., Comparing practices to prevent infectious diseases transmission among Veterans Affairs and Nonveterans Affairs hospitals: Results from a national survey in the United States. *Am J Infect Control*, 2024. 52(4): p. 495-497.
16. The, L., Privatising versus prioritising veterans' health. *Lancet*, 2018. 391(10128): p. 1332.
17. Tummalapalli, S.L. and S. Keyhani, Trends in Preventative Health Services for Veterans with Military Coverage Compared to Non-Military Coverage. *J Gen Intern Med*, 2020. 35(4): p. 1330-1333.
18. Vanneman, M.E., et al., Veterans' Experiences With Outpatient Care: Comparing The Veterans Affairs System With Community-Based Care. *Health Aff (Millwood)*, 2020. 39(8): p. 1368-1376.
19. Wachterman, M.W., et al., A comparison of end-of-life care quality for Veterans receiving hospice in VA nursing homes and community nursing homes. *J Am Geriatr Soc*, 2024. 72(1): p. 59-68.

Ineligible Publication Type, N = 11

1. Garvin, L.A., et al., Interorganizational Care Coordination of Rural Veterans by Veterans Affairs and Community Care Programs: A Systematic Review. *Med Care*, 2021. 59(Suppl 3): p. S259-S269.
2. Gordon, S.H., et al., County-level Predictors of Growth in Community-based Primary Care Use Among Veterans. *Med Care*, 2021. 59(Suppl 3): p. S301-S306.
3. Greenstone, C.L., et al., Standardizing Care Coordination Within the Department of Veterans Affairs. *Journal of General Internal Medicine*, 2019. 34(1): p. 4-6.
4. Hynes, D.M., et al., Veterans' Use of Veterans Health Administration Primary Care in an Era of Expanding Choice. *Med Care*, 2021. 59(Suppl 3): p. S292-S300.
5. Mattocks, K.M., et al., Understanding VA's Use of and Relationships With Community Care Providers Under the MISSION Act. *Med Care*, 2021. 59(Suppl 3): p. S252-S258.
6. Nuti, S.V., L. Qin, and H.M. Krumholz, Outcome After Admission at Veterans Affairs vs Non-Veterans Affairs Hospitals--Reply. *Jama*, 2016. 316(3): p. 346.
7. O'Hanlon, C.E., C. Farmer, and C. Gidengil, Comparing VA to Non-VA Care. *J Gen Intern Med*, 2017. 32(2): p. 152.
8. Radomski, T.R., M.J. Fine, and W.F. Gellad, Outcome After Admission at Veterans Affairs vs Non-Veterans Affairs Hospitals. *Jama*, 2016. 316(3): p. 345-6.
9. Ramkumar, M. and S.T. Crowley, Kidney Transplantation Rates of Veterans Administration-Listed Patients Compared with Rates of Patients on Nonveteran Lists. *J Am Soc Nephrol*, 2018. 29(10): p. 2449-2450.
10. Vashi, A.A., et al., Community Urgent Care Use Following Implementation of the Veterans Affairs Maintaining Internal Systems and Strengthening Integrated Outside Networks Act. *Med Care*, 2021. 59(Suppl 3): p. S314-S321.
11. Weeks, W.B., Comparing VA to Non-VA Care. *J Gen Intern Med*, 2017. 32(2): p. 150-151.

Ineligible Design (Non-Research), N = 7

1. Cordasco, K.M., et al., Coordinating Care Across VA Providers and Settings: Policy and Research Recommendations from VA's State of the Art Conference. *Journal of General Internal Medicine*, 2019. 34(1): p. 11-17.
2. Cordasco, K.M., et al., Improving Care Coordination for Veterans Within VA and Across Healthcare Systems. *Journal of General Internal Medicine*, 2019. 34(1): p. 1-3.



3. Gittell, J.H. and L. Hajjar, Strengthening Patient-Centered Care in the VHA: A Relational Model of Change. *Journal of General Internal Medicine*, 2019. 34(1): p. 7-10.
4. Mattocks, K.M., et al., Recommendations for the Evaluation of Cross-System Care Coordination from the VA State-of-the-art Working Group on VA/Non-VA Care. *Journal of General Internal Medicine*, 2019. 34(1): p. 18-23.
5. Mattocks, K.M., et al., Innovations in Community Care Programs, Policies, and Research. *Med Care*, 2021. 59(Suppl 3): p. S229-S231.
6. McDonald, K.M., et al., Incorporating Theory into Practice: Reconceptualizing Exemplary Care Coordination Initiatives from the US Veterans Health Delivery System. *Journal of General Internal Medicine*, 2019. 34(1): p. 24-29.
7. Mengeling, M.A., et al., Partnership Forum: The Role of Research in the Transformation of Veterans Affairs Community Care. *Med Care*, 2021. 59(Suppl 3): p. S232-S241.

Unrepresentative Sample or Comparison, N = 2

1. Dizon, M.P., et al., Comparing the Quality of Ambulatory Surgical Care for Skin Cancer in a Veterans Affairs Clinic and a Fee-For-Service Practice Using Clinical and Patient-Reported Measures. *PLoS One*, 2017. 12(1): p. e0171253.
2. Geraci, T., et al., Lobectomy for Lung Cancer at Veterans Administration Medical Center Versus Academic Medical Center. *Ann Thorac Surg*, 2017. 103(6): p. 1715-1722.

STUDY CHARACTERISTICS

NON-SURGICAL CARE

Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
Nuti, 2016 ²⁷ Y (National) Retrospective Acute myocardial infarction, heart failure, pneumonia Clinical quality/safety	2013-2016, vs. other non- VA; CMS Standard Analytic Files and Enrollment Database vs. VA administrative claims	N: 7929-26,231 Mortality (AMI): M 13.52/30d, 95% CI 13.38 to 13.66; Mortality (HF): M 11.43/30d, 95% CI 11.11 to 11.75; Mortality (Pneu): M 12.63/30d, 95% CI 12.19 to 13.07; Readmissions (AMI): M 17.84/30d, 95% CI 17.71 to 17.96; Readmissions (HF): M 24.66/30d, 95% CI 24.31 to 25.02; Readmissions (Pneu): M 19.44/30d, 95% CI 19.19 to 19.69	N: 124,220-269,856 Mortality (AMI): M 13.69/30 d, 95% CI 13.64 to 13.74; Mortality (HF): M 11.87/30d, 95% CI 11.80 to 11.93; Mortality (Pneu): M 12.17/30d, 95% CI 12.08 to 12.26; Readmissions (AMI): M 17.21/30d; 95% CI 17.17 to 17.25; Readmissions (HF): M 23.46/30d; 95% CI 23.39 to 23.53; Readmissions (Pneu): M 18.68/30d; 95%CI 18.63 to 18.73	Mortality (AMI): VA<non-VA,p=0.02; Mortality (HF): VA<non- VA, p=0.008; Mortality (Pneu): VA>non-VA, p=0.045; Readmissions (AMI): VA>non-VA, p<0.001; Readmissions (HF): VA>non-VA, p<0.001; Readmissions (Pneu): VA>non-VA, p<0.001;	<u>Statistics:</u> Hierarchical logistic regression to estimate values; t-tests to compare <u>Other methods of controlling:</u> NR <u>Covariates:</u> Age, patient cardiovascular medical history, comorbid conditions, hospital random effects	Y	
Vanneman, 2020 ⁵⁰ Y (National) Retrospective Outpatient specialty, primary, and mental health care Access Patient experience	2016-2017, vs Veterans in VA-paid community care; SHEP vs CAHPS	N=29,095-432,218 (combined VA and non- VA) NR	N=29,095-432,218 (combined VA and non- VA) NR	Access to care (specialty care): -0.0023 (VA vs non-VA; p=ns); Access to care (primary care): -0.0003 (VA vs non-VA; p=ns); Access to care (mental health): -0.001 Patient experience (specialty care): 0.0005 (VA vs non-VA; p=ns);	<u>Statistics:</u> Multivariate regression models <u>Other methods of controlling:</u> NR <u>Covariates:</u> age, sex, race, ethnicity, education level, marital status, rurality, VA enrollment priority, and Nosos health risk score, perceived physical health status, perceived mental health status, insurance status,	Y	Regression coefficients over entire time period reported



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
				Patient experience (primary care): -0.0137 (VA vs non-VA; p=ns); Patient experience (mental health): -0.0218 (VA vs non-VA; p=ns);	number of days between the outpatient visit and survey return date, and VA facility fixed effects		
Gurewich, 2021 ⁴⁷ Y (National) Retrospective Physical therapy, cardiology, optometry, dental care, and orthopedics Access	2014-2018 (FY15-FY18), vs Veterans in VA-paid community care; CDW (both VA and non-VA)	N=420,590 (FY15), 487,014 (FY18) FY15 (wait time in days for urban Veterans): Physical therapy: 30.62 Cardiology: 26.77 Optometry: 42.84 Orthopedic: 35.26 Dental: 27.70; FY18 (wait time in days for urban Veterans): Physical therapy: 26.26 Cardiology: 24.15 Optometry: 34.32 Orthopedic: 27.73 Dental: 24.01;	N=76,706 (FY15), 150,429 (FY18) FY15 (wait time in days for urban Veterans): Physical therapy: 28.94 Cardiology: 28.46 Optometry: 41.85 Orthopedic: 37.35 Dental: 25.99; FY18 (wait time in days for urban Veterans): Physical therapy: 28.84 Cardiology: 27.55 Optometry: 36.90 Orthopedic: 32.87 Dental: 25.90;	VA had greater wait time declines from FY15 to FY18 than non-VA except for cardiology (p<0.001)	<u>Statistics:</u> Linear regression <u>Other methods of controlling:</u> NR <u>Covariates:</u> Rurality, age, sex, race/ethnicity, marital status, FY, Nosos score, priority level, age/sex*FY18 interactions	Y	NA
Davila, 2021 ⁵¹ Y (National) Retrospective Primary and specialty care Access Patient experience	FY16-FY19, vs Veterans in VA-paid community care; SHEP and CDW (both VA and non-VA)	N=1,019,732 FY16 (primary care, access, urban): 3.18; FY16 (specialty care, access, urban): 3.09; FY19 (primary care, access, urban): 3.27; FY19 (specialty care, access, urban): 3.17; FY16 (primary care, access, rural): 3.24; FY16 (specialty care, access, rural): 3.15;	N=63,638 FY16 (primary care, access, urban): 2.91; FY16 (specialty care, access, urban): 3.17; FY19 (primary care, access, urban): 3.12; FY19 (specialty care, access, urban): 3.28; FY16 (primary care, access, rural): 3.11; FY16 (specialty care, access, rural): 3.17;	FY 16 VA vs CC (rural, primary care, access): 0.17; FY 19 VA vs CC (rural, primary care, access): 0.21; FY 16 VA vs CC (rural, specialty care, access): -0.02; FY 19 VA vs CC (rural, specialty care, access): -0.07;	<u>Statistics:</u> Multiple regression models <u>Other methods of controlling:</u> NR <u>Covariates:</u> Age, sex, race, education level, marital status, VA enrollment priority, Nosos risk score, and self-rated physical and mental health	Y	SHEP scores analyzed in raw column, effect sizes reported in comparison column; "Effect sizes [ESs] of 0.10 are often interpreted as indicating 'negligible' differences between groups; ESs of 0.20, 0.50, and 0.80 are



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
		FY19 (primary care, access, rural): 3.31; FY19 (specialty care, access, rural): 3.23 ; FY16 (primary care, provider rating, urban): 8.83; FY16 (specialty care, provider rating, urban): 8.69; FY19 (primary care, provider rating, urban): 8.92; FY19 (specialty care, provider rating, urban): 8.88; FY16 (primary care, provider rating, rural): 8.80; FY16 (specialty care, provider rating, rural): 8.73; FY19 (primary care, provider rating, rural): 8.90; FY19 (specialty care, provider rating, rural): 8.92	FY19 (primary care, access, rural): 3.16; FY19 (specialty care, access, rural): 3.28; FY16 (primary care, provider rating, urban): 7.28; FY16 (specialty care, provider rating, urban): 8.46; FY19 (primary care, provider rating, urban): 8.30; FY19 (specialty care, provider rating, urban): 8.70; FY16 (primary care, provider rating, rural): 8.14; FY16 (specialty care, provider rating, rural): 8.43; FY19 (primary care, provider rating, rural): 8.56; FY19 (specialty care, provider rating, rural): 8.72	FY 16 VA vs CC (rural, primary care, provider rating): 0.35; FY 19 VA vs CC (rural, primary care, provider rating): 0.19; FY 16 VA vs CC (rural, specialty care, provider rating): 0.16; FY 19 VA vs CC (rural, specialty care, provider rating): 0.12			considered 'small,' 'medium,' and 'large,' respectively"
Intrator, 2021 ³⁰ Y (National) Retrospective Nursing homes Clinical quality/safety	2015-2016, vs non-Veterans in non-VA nursing homes; Vets and non-Vets in MDS, VA data (unspecified), and Medicare claims	N=23,839 Rehospitalization: M 22.51, SD 6.17; Emergency department visits: M 8.27, SD 4.56; Successful discharge: M 67.74, SD 11.47	N=1,674,578 Rehospitalization: M 21.10 SD, 5.94; Emergency department visits: M 11.85, SD 5.32; Successful discharge: M 57.04, SD 10.54	Rehospitalization: VA>non-VA, p<0.001; Emergency department visits: VA<non-VA, p<0.001; Successful discharge: VA>non-VA, p<0.001	<u>Statistics:</u> 2-sample z test <u>Other methods of controlling:</u> NR <u>Covariates:</u> CMS risk adjust model, including age, marital status, length of stay, medication utilization, treatments, comorbidities, and activities of daily living	Y	NA



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
LaBedz, 2021 ³⁸ Y (National) Retrospective COPD Clinical quality/safety	2015-2018, vs all patients in non-VA hospitals; CMS Hospital Compare (VA vs non-VA)	N=126 Readmissions: M 15.3, standard error (SE) 0.17; Mortality: M 6.0, SE 0.11	N=3523 Readmissions: M 19.5 SE, 0.2; Mortality: M 8.5 SE, 0.02	Readmissions: VA<non-VA, M -4.2, 95% CI -4.5 to -3.9; Mortality: VA<non-VA, M -2.6, 95% CI -2.8 to -2.4	<u>Statistics:</u> T-tests, linear regression <u>Other methods of controlling:</u> NR <u>Covariates:</u> Age, comorbid conditions, and indicators of frailty	Y	Supplementary analyses: Increased readmission were associated with lower mortality for non-VA hospitals (p=0.003; “50 fewer deaths per 1000 more readmissions”); no association was found for VA hospitals
Gidwani, 2021 ⁵³ Y (National) Retrospective Cancer Cost/efficiency	FY10-FY14, vs Veterans in non-VA hospitals; VA administrative data vs Medicare claims	N=10,341 NR	N=18,542 NR	Total costs: VA<Medicare; beta-coeff: M -0.1, 95% CI -0.15 to -0.06; Inpatient costs: VA<Medicare; beta-coeff: M -0.12, 95% CI -0.22 to -0.02; Outpatient costs: VA<Medicare; beta-coeff: M -0.31, 95% CI -0.35 to -0.28; Drug costs: VA>Medicare; beta-coeff: M -0.71, 95% CI 0.64 to 0.78	<u>Statistics:</u> Generalized estimating equations <u>Other methods of controlling:</u> Three-level models <u>Covariates:</u> Age, race, distance from VA facility, rurality, enrollment priority, and type of solid tumor, and conditioning on geographic region	Y	NA
Griffith, 2020 ⁴⁸ Y (National) Retrospective Cardiology, gastroenterology,	2018-2019, vs Veterans in VA-paid community care; VA CDW (for VA and non-VA)	N=2,504,355 consultations Cardiology: M 33d, SD 8.7d;	N=533,609 consultations Cardiology: M 38.0d, SD 9.2d;	NR	NR	Y	>50% of VA facilities had lower wait times for cardiology, orthopedics,



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
orthopedics, and urology Access		Gastroenterology: M 53.9 SD 15.9d; Orthopedics: M 36.2d SD 9.3d; Urology: M 36.1d SD 9.5d; Overall: M 41.1d SD 15.9d	Gastroenterology: M 60.3d SD 16.0d; Orthopedics: M 43.6d SD 12.9d; Urology: M 50.5d SD 14.5d; Overall: M 49.0d SD 15.5d				urology, and overall
Gidwani- Marszowski, 2020 ⁴³ Y (National) Retrospective Cancer Clinical quality/safety	FY10-FY14, vs Veterans in non-VA care; VA and Medicare administrative data	N=9522 444 potentially avoidable hospitalizations	N=17,921 1271 potentially avoidable hospitalizations	Medicare vs VA: adjusted odds ratio 1.55, 95% CI 1.37 to 1.66	<u>Statistics:</u> Generalized estimating equations with a logit link and a binomial family <u>Other methods of controlling:</u> Patients nested within geographic area (hospital referral region) <u>Covariates:</u> Age, number of chemotherapy treatments, receipt of concurrent radiotherapy (defined as radiotherapy within 14 days of the receipt of chemotherapy), and cancer type	Y	Sensitivity analysis covariates: enrollment priority, race, rurality, and distance from a VA facility
Penn, 2019 ⁴⁶ Y (National) Retrospective Primary care, dermatology, cardiology, orthopedics Access	2014-2017, vs non- Veterans in non-VA community care; VA administrative data vs Merritt Hawkins secret shopper survey	N=NR, 15 metropolitan areas in 2014, 30 metropolitan areas in 2017 NR	N=NR, 15 metropolitan areas in 2014, 30 metropolitan areas in 2017 NR	VA vs non-VA, 2014: Primary care: ns; Dermatology: ns; Cardiology: ns; Orthopedics: M 9.9d SD 4.7d vs M 23.9d SD 8.1d, p<.001; Overall: ns; VA vs non-VA, 2017:	<u>Statistics:</u> Linear regression <u>Other methods of controlling:</u> NR <u>Covariates:</u> Metropolitan area, specialty	Y	



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
				Primary care: M 20.0d SD 10.4d vs M 40.7d SD 35.0d, p=0.005; Dermatology: M 15.6 d SD 12.2d vs M 32.6d SD 16.5d, p<0.001; Cardiology: M 15.3d SD 12.6d vs M 22.8d SD 10.1d, p=0.04; Orthopedics: M 20.9d SD 13.3d vs M 12.4d SD 5.5d, p=0.01; Overall: ns			
Makarov, 2018 ⁵² Y (National) Retrospective Cancer Clinical quality/safety Cost/efficiency	2004-2008, vs non- Veterans in non-VA care; CDW vs SEER Medicare	N=27,811 Low-risk men: Guideline-concordant care: 60.6%; Any imaging: 45.9%; High-risk men: Guideline-concordant care: 68.7%; Any imaging: 75.3%	N=56,671 Low-risk men: Guideline-concordant care: 53.1%; Any imaging: 52.5%; High-risk men: Guideline-concordant care: 66.8%; Any imaging: 76.8%	No statistical comparisons reported	<u>Statistics:</u> NR <u>Other methods of controlling:</u> NR <u>Covariates:</u> NR	Y	
Wang, 2019 ³² Y (National) Retrospective ESRD Clinical quality/safety	2008-2013, vs Veterans in VA-paid community care; VA enrollment, inpatient, outpatient, and purchased care data vs Medicare enrollment, claims, and USRDS data	N=1100; Two-year mortality: 24.5%	N=18,215 Two-year mortality: 41.8%	VA vs Medicare, two- year mortality: hazard ratio 0.84 95% CI 0.73 to 0.96	<u>Statistics:</u> Cox proportional hazards model <u>Other methods of controlling:</u> NR <u>Covariates:</u> Age, race/ethnicity, sex, employment status, regional and urban residential status, calendar year of dialysis initiation, baseline eGFR at dialysis initiation, receipt of pre-ESRD nephrology care within or outside the VA in the 2 years before ESRD onset, incident	Y	



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
Thorpe, 2018 ²⁸ Y (National) Retrospective Dementia Clinical quality/safety	2007-2010, Veterans in non-VA care; VA Medical SAS and VA PBM vs Medicare MedPAR, Part D, and MBSF	N=35,647 Medication undersupply with no oversupply: 40%; Medication oversupply with no undersupply: 9%; Simultaneous medication oversupply and undersupply: 4%	N=9922 Medication undersupply with no oversupply: 47%; Medication oversupply with no undersupply: 5%;	Non-VA vs VA, odds ratio: Medication undersupply with no oversupply: 1.13 95% CI 1.03 to 1.25; Medication oversupply with no undersupply: 0.39 95% 0.32 to 0.47;	dialysis modality, type of vascular access at time of dialysis initiation, history of renal transplant, cause of ESRD, 29 indicators of diagnosed physical health conditions and mental health comorbidity, body mass index, hospitalization and institutionalization in the year before dialysis initiation, hospice use in the 90 days before dialysis initiation, dialysis in the inpatient setting, insurance coverage, VA copayment exempt status, distance to nearest VA outpatient dialysis unit and VAMC, degree of VA reliance for other outpatient care, presence of dialysis unit or nephrology services in nearest or most used VAMC, and FY11 occupancy rate of nearest VA outpatient dialysis unit. Statistics: Multinomial logistic regression <u>Other methods of controlling:</u> NR <u>Covariates:</u> Age, sex, race/ethnicity, VA priority status, Medicaid status, distance to nearest	Y	



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
			Simultaneous medication oversupply and undersupply: 3%	Simultaneous medication oversupply and undersupply: 0.48 95% CI 0.40 to 0.57	VAMC, Elixhauser Comorbidity Index, use of memantine, number of VA ED and inpatient stays and use of VA home-based primary care in 2009, days alive in 2010, number of unique generic medications in 2010, and VISN indicator		
Vercammen-Grandjean, 2018 ³⁹ Y (National) Retrospective COPD Clinical quality/safety	2007-2011, vs non-Veterans in non-VA care; CDW vs Medicare inpatient files	N=32,856 Participation in pulmonary rehabilitation after hospital discharge: N=485	N=158,137 Participation in pulmonary rehabilitation after hospital discharge: N=3199	VA vs non-VA; Participation in pulmonary rehabilitation after hospital discharge: 1.5% vs 2%	<u>Statistics:</u> None <u>Other methods of controlling:</u> NR <u>Covariates:</u> NR	Y	No formal statistical comparison between VA and non-VA but sample size is large enough to estimate a significant difference
Wang, 2018 ³³ Y (National) Retrospective Dialysis patients Clinical quality/safety Cost/efficiency	2006-2013, vs Veterans in VA-paid community care; VA Enrollment, MiniVitals, Patient Treatment, Outpatient Care, Fee Basis files vs Medicare Beneficiary Summary, MedPAR, Outpatient, and Carrier files, and USRDS data	N=1101 Number of hospital days over 2 years follow-up period from chronic dialysis initiation: M 24.1 SD (37.2)	N=3085 (VA Purchase Care) N=18,267 (Medicare) Number of hospital days over 2 years follow-up period from chronic dialysis initiation: VA-PC: M 22.4 SD (29.3); Medicare: M 21.9 SD (26.0)	Number of hospital days over 2 years follow-up period from chronic dialysis initiation: VA vs VA-PC, incident rate ratio 0.97 95% CI 0.91 to 1.03,p=0.34; vs Medicare, incident rate ratio 0.98 95% CI 0.90 to 1.07,p=0.73; VA vs VA-PC or Medicare: Risk of hospitalization after dialysis: p<0.0001, but authors note differences are not clinically meaningful;	<u>Statistics:</u> Zero inflated negative binomial regression model <u>Other methods of controlling:</u> NR <u>Covariates:</u> Sex, urban vs non-urban residence, year of chronic dialysis start date, employment status, factors surrounding dialysis initiation that would influence treatment setting (e.g., pre-ESRD nephrology care within or outside the VA, incident dialysis modality, type of vascular access at time of dialysis	Y	Outcomes not significantly different between healthcare systems



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
				Days of hospitalization after dialysis: p=0.80	initiation, history of prior kidney transplant, cause of ESRD), distance to the nearest VA medical center (VAMC, i.e., the center most frequently used for non-dialysis care, else the nearest VAMC to residence), the extent of VA reliance for other outpatient care, initiated dialysis in the inpatient vs outpatient setting, 29 indica- tors of diagnosed physical health conditions, BMI, hospitalization and institutionalization in the prior year, hospice use in the past 90 days, whether nearest VAMC had an on-site nephrology services or dialysis unit, and the 2011 fiscal year occupancy rate for nearest VAMC facility		
Augustine, 2018 ¹⁶ Y (Regional) Retrospective Kidney transplants Access Clinical quality/safety Access	2004-2016, non-Veterans in non-VA care; SRTR (VA and non-VA data)	N=3663 Median distance to transplant center: 282 miles	N=297,794 Median distance to transplant center: 22 miles	All kidney transplants: VA vs non-VA: adjusted hazard ratio (AHR) 0.72, 95% CI 0.68 to 0.76; VA vs Medicare: AHR 0.85, 95% CI 0.81 to 0.90; VA vs Medicaid: AHR 1.00, 95% CI 0.94 to 1.06; Deceased donor kidney transplant:	<u>Statistics:</u> Cox models <u>Other methods of controlling:</u> Matching VA to local non-VA facility <u>Covariates:</u> Age group, race, gender, diagnosis group, time on dialysis at listing, candidate status at listing, panel reactive antibody, BMI group, education, malignancy, peripheral	N	Note: * = p<0.05; RoB criteria not met: unbalanced samples



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
				VA vs non-VA: AHR 0.85, 95% CI 0.80 to 0.90; VA vs Medicare: AHR 0.91, 95% CI 0.85 to 0.96; VA vs Medicaid: AHR 1.01, 95% CI 0.95 to 1.08; Live donor kidney transplant: VA vs non-VA: AHR 0.51, 95% CI 0.46 to 0.57; VA vs Medicare: AHR 0.77, 95% CI 0.69 to 0.86; VA vs Medicaid: AHR 1.00, 95% CI 0.89 to 1.12; Patient death: VA vs non-VA: AHR 0.89, 95% CI 0.82 to 0.97; VA vs Medicare: AHR 0.77, 95% CI 0.71 to 0.84; VA vs Medicaid: AHR 0.76, 95% CI 0.70 to 0.83; Delisting from kidney transplant list due to "health deterioration" or "other": VA vs non-VA: AHR 1.38, 95% CI 1.26 to 1.51; VA vs Medicare: AHR, 1.1 95% CI 1.001 to 1.2;	vascular disease, region, year of listing, log distance to center and community risk score		



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
				VA vs Medicaid: AHR 1.04, 95% CI 0.95 to 1.05			
Anhang Price, 2018 ³⁷ Y (National) Retrospective Inpatient and outpatient care Clinical quality/safety Patient experience	2014, vs non-Veterans in non-VA care; CMS Hospital Compare (VA), VA Inpatient Evaluation Center, and VA Office of Performance Measurement vs CMS Hospital Compare (non-VA)	N=135 facilities In-hospital deaths per 1000 surgical discharges with serious treatable complications (inpatient): 100.6; Postoperative pulmonary embolism or deep vein thrombosis rate (inpatient): 3.3; Acute myocardial infarction 30-day readmission rate (inpatient): 18.6; Heart failure 30-day mortality rate (inpatient): 11; Evaluation of left ventricular systolic (LVS) function (inpatient): 99.8; Prophylactic antibiotic received within 1 h prior to surgical incision (inpatient): 96.3; Communication with doctors (inpatient): 77.1; Care transition (inpatient): 53.7; Overall rating of hospital (inpatient): 67.1; Diabetes: Eye examination: 95.9%; Tobacco use: advising smokers and tobacco users to quit (outpatient): 90.0%; Hypertension: Controlling high blood pressure	N=402 facilities In-hospital deaths per 1000 surgical discharges with serious treatable complications (inpatient): 118.8; Postoperative pulmonary embolism or deep vein thrombosis rate (inpatient): 4.6; Acute myocardial infarction 30-day readmission rate (inpatient): 17.8; Heart failure 30-day mortality rate (inpatient): 11.8; Evaluation of left ventricular systolic (LVS) function (inpatient): 98.5; Prophylactic antibiotic received within 1 h prior to surgical incision (inpatient): 98.5; Communication with doctors (inpatient): 80.3; Care transition (inpatient): 43.3; Overall rating of hospital (inpatient): 70.3; Diabetes: Eye examination: 84.6% Tobacco use: advising smokers and tobacco users to quit (outpatient): 68.5%;	All VA and non-VA differences significant (p<0.05); last 3 comparisons: VA vs Medicare HMO	<u>Statistics:</u> T-tests <u>Other methods of controlling:</u> Matching VA to local non-VA facility <u>Covariates:</u> Bed size (< 100 beds, 100–199 beds, and 200+ beds), Census division (East North Central, East South Central, Mid- Atlantic, Mountain, New England, Other, Pacific, South Atlantic, West North Central, and West South Central), location (urban, rural), and teaching status (teaching facility, nonteaching fa- cility)	Y	



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
		(diagnosis of hypertension, 18–85 years and < 140/90 mmHg): 76.1%	Hypertension: Controlling high blood pressure (diagnosis of hypertension, 18–85 years and < 140/90 mmHg): 65.5%				
Kurella Tamura, 2018 ³⁴ Y (National) Retrospective Pre-ESRD nephrology care Clinical quality/safety	2008-2011, vs Veterans in non-VA care; VA administrative data vs Medicare Claims, USRDS (both)	N=2966 Dialysis treatment within 2 years of incident kidney failure in pre-ESRD patients: 50.9%	N=2966 Dialysis treatment within 2 years of incident kidney failure in pre-ESRD patients: 79.2%	Medicare vs VA Dialysis treatment within 2 years of incident kidney failure in pre-ESRD patients: relative risk 1.56 95% CI 1.50 to 1.62; Mortality after receiving dialysis care for pre-ESRD patients: -8%, 95% CI -5% to -11%;	<u>Statistics:</u> Poisson regression; marginal standardization <u>Other methods of controlling:</u> Propensity score matching <u>Covariates:</u> Age, sex, race, marital status, VA co-pay, distance to nearest VA with nephrology services, Charlson Comorbidity Index, and rate of eGFR decline prior to incident kidney failure	Y	
Barnett, 2018 ²⁶ Y (National) Retrospective Elective coronary revascularization patients (PCI & CABG) Clinical quality/safety Access Cost/efficiency	2008-2011, vs Veterans in VA-paid community care; VA and non-VA: ArcGIS, VA Vital Status File, VA Managerial Cost Accounting System	N=15,340 Total cost (procedure + readmission + travel), PCI: M \$15,683.00 SD (\$16,493.00); Total cost (procedure + readmission + travel), CABG: M \$63,144.00 SD (\$46,018.00); Actual distance traveled, PCI: M 90.8 Actual distance traveled, CABG: M 123.2	N=3715 Total cost (procedure + readmission + travel), PCI: M \$22,025.00 SD (\$30,701.00); Total cost (procedure + readmission + travel), CABG: M \$55,526.00 SD (\$74,797.00); Actual distance traveled, PCI: M 60.1 Actual distance traveled, CABG: M 81.5	30-day mortality, PCI: VA>non-VA, relative risk (RR) 2.40 95% CI 1.57 to 3.66, p<0.001; 30-day mortality, CABG: VA=non-VA, RR 0.89 95% CI 0.45 to 1.77, p=0.74; 30-day readmissions, PCI: VA=non-VA, RR 0.96 95% CI 0.79 to 1.16, p=0.68; 30-day readmissions, CABG: VA=non-VA, RR 1.16 95% CI 0.89 to 1.50, p=0.28; Total cost (procedure + readmission + travel), PCI: VA<non-VA, p<0.001;	<u>Statistics:</u> Generalized estimating equations <u>Other methods of controlling:</u> Propensity weighting <u>Covariates:</u> age, sex, race/ethnicity, recent myocardial infarction, prior PCI, prior CABG surgery, cerebrovascular disease, peripheral vascular disease, congestive heart failure, type 1 and type 2 diabetes, body mass index, renal function, dialysis, chronic obstructive pulmonary disease, atrial fibrillation, and the	Y	



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
				Total cost (procedure + readmission + travel), CABG: VA>non-VA, p<0.001; Actual distance traveled, PCI: VA>non-VA, p<0.001; Actual distance traveled, CABG: VA>non-VA, p=0.002	number of vessels revascularized		
Heidenrich, 2017 ²¹ Y (National) Retrospective Hospital care Patient experience	2014; vs non-Veterans in non-VA care; Yelp (both)	N=39 facilities Patient ratings (weighted for number of reviews): M 3.70 SD 0.74	N=39 facilities Patient ratings (weighted for number of reviews): M 3.19 SD 0.54	VA vs non-VA: Difference in ratings, weighted by review count: p=0.0025 Covariate adjusted rating difference 0.65, 95% CI 0.18 to 1.12	<u>Statistics:</u> Multivariate regression <u>Other methods of controlling:</u> Local affiliate matching <u>Covariates:</u> Bed size, membership in COTH, presence of an accredited graduate medical education program, and certification by TJC	N	RoB criteria not met: analysis of Yelp reviews of only 39 of 131 VA facilities due to lack of data
Blay, 2017 ³⁶ Y (National) Retrospective Hospital care Clinical quality/safety Patient experience	2012-2015, vs non-Veterans in non-VA care; Both VA and non-VA: Hospital Compare, AHA Annual Survey	N=129 facilities Pressure ulcers: M 0.28, 95% CI 0.21 to 0.27; Death among surgical inpatients with serious treatable conditions: M 105.82, 95% CI 96.7 to 114.92; Iatrogenic pneumothorax: M 0.27, 95% CI 0.22 to 0.32; 30-day mortality, AMI: 9.27, 95% CI 9.0 to 9.46; 30-day readmissions, AMI: M 15.59 95% CI, 15.45 to 15.74; Doctor communication: top box 76.70%, 95% CI 76.01 to 77.39%;	N=4010 facilities Pressure ulcers: M 0.44, 95% CI 0.44 to 0.46; Death among surgical inpatients with serious treatable conditions: M 136.34, 95% CI 135.42 to 137.26; Iatrogenic pneumothorax: M 0.41, 95% CI 0.40 to 0.41; 30-day mortality, AMI: M 14.1, 95% CI 14.04 to 14.15; 30-day readmissions, AMI: M 16.89, 95% CI 16.84 to 16.94; Doctor communication:	VA<non-VA for all clinical quality/safety outcomes, p<0.03; Non-VA>VA for all patient experience outcomes (p<0.005) except cleanliness and care transition	<u>Statistics:</u> T-tests <u>Other methods of controlling:</u> Outcomes were rates per 1000 discharges; Bonferroni correction <u>Covariates:</u> NR	Y	



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
		Cleanliness: top box 73.41% 95% CI 71.95 to 74.87%; Care transition: top box 53.62%, 95% CI 51.79% to 54.46%; Quietness: 55.80% , 95% CI 54.24% to 57.37%; Recommendation of hospital to others: top box, 67.92% 95% CI 66.56 to 69.28%;	top box 82.14%, 95% CI 81.95 to 82.32%; Cleanliness: 74.14%, 95% CI 73.86% to 74.41%; Care transition: top box 52.71%, 95% CI 52.47% to 52.96%; Quietness: top box 62.93 %, 95% CI 62.59% to 63.26%; Recommendation of hospital to others: top box 71.66%, 95% CI 71.33% to 71.99%				
Mody, 2017 ²² N (NA) Prospective survey Nursing home care Clinical quality/safety	2014-2015; vs non-Veterans in non-VA care; Original surveys (both VA and non-VA data)	N=47 facilities Policy for appropriate indications for catheter use: 63.8%; Policy for urinary catheter maintenance: 78.7%; Urinary catheters removed within 24–48 hrs. of admission unless there are appropriate: 74.5%; Catheter-associated urinary tract infection surveillance performed: 93.6%	N=306 facilities Policy for appropriate indications for catheter use: 81.4%; Policy for urinary catheter maintenance: 92.8%; Urinary catheters removed within 24–48 hrs. of admission unless there are appropriate: 93.8%; Catheter-associated urinary tract infection surveillance performed: 65.7%	Policy for appropriate indications for catheter use: VA<non-VA, p=0.004; Policy for urinary catheter maintenance: VA<non-VA, p=0.001; Urinary catheters removed within 24–48 hrs. of admission unless there are appropriate: VA<non-VA, p<0.001; Catheter-associated urinary tract infection surveillance performed: VA>non-VA, p<0.001	<u>Statistics:</u> Multivariable logistic regression models <u>Other methods of controlling:</u> All nursing homes participating in AHRQ HAI/CAUTI patient safety collaborative <u>Covariates:</u> Number of residents in facility, short-term sub-acute rehabilitation offered, presence of an HAI committee, infection prevention training, and infection preventionist with 3 or more years of experience	N	RoB criteria not met: data from only half of states
Shields, 2017 ²⁴ Y (National) Retrospective Psychiatric care	2014, vs non-Veterans in non-VA care; HBIPS	N=105 facilities NR	N=141 facilities (for-profit), 180 (non-VA government) NR	For-profit vs VA: Admissions screening for inpatient psychiatric care: 37.2%, p<0.001;	<u>Statistics:</u> T-tests <u>Other methods of controlling:</u> NR <u>Covariates:</u> NR	N	RoB criteria not met: no adjustment for patient characteristics



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
Clinical quality/safety				Restraint hours per 1000 patient hours: - 77.9%, p=0.004; Seclusion hours per 1000 patient hours: - 61.6%, p=0.01; Creating a continuing care plan at discharge: 41.7%, p<0.001; Transmitting a continuing care plan at discharge: 40.4%, p<0.001; Non-VA government vs VA: Appropriate justification of antipsychotics at discharge: 33.9%, p<0.001			
Burke, 2016 ¹⁷ Y (National) Retrospective Headache and neuropathy Clinical quality/safety	2004-2011, vs non-Veterans in non-VA care; CDW vs MedPAR/HRS	N=256,608 Imaging for nontraumatic headache: 22.1%; Imaging for nontraumatic headache excluding cancer, hemiplegic migraine, giant cell arteritis, epilepsy, cerebrovascular disease including TIA, head or neck trauma, altered mental status, personal history of stroke/TIA or cancer, multiple sclerosis, or dementia: 15.3%; Imaging for migraine excluding cancer, hemiplegic migraine, giant cell arteritis, epilepsy, cerebrovascular disease including TIA,	N=2005 Imaging for nontraumatic headache: 49.0%; Imaging for nontraumatic headache excluding cancer, hemiplegic migraine, giant cell arteritis, epilepsy, cerebrovascular disease including TIA, head or neck trauma, altered mental status, personal history of stroke/TIA or cancer, multiple sclerosis, or dementia: 27.1%; Imaging for migraine excluding cancer, hemiplegic migraine,	VA<non-VA for all outcomes, p<0.001; except for imaging for migraine, p=0.027	<u>Statistics:</u> T-tests <u>Other methods of controlling:</u> NR <u>Covariates:</u> NR	N	RoB criteria not met: unbalanced samples



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
		head or neck trauma, altered mental status, personal history of stroke/TIA or cancer, multiple sclerosis, or dementia: 7.1%; Neuroimaging any component of neuroaxis: 9%; Neuroimaging any component of neuroaxis excluding cancer, hemiplegic migraine, giant cell arteritis, epilepsy, cerebrovascular disease including TIA, head or neck trauma, altered mental status, personal history of stroke/TIA or cancer, multiple sclerosis, or dementia: 6.1%	giant cell arteritis, epilepsy, cerebrovascular disease including TIA, head or neck trauma, altered mental status, personal history of stroke/TIA or cancer, multiple sclerosis, or dementia: 15.6%; Neuroimaging any component of neuroaxis: 23.7%; Neuroimaging any component of neuroaxis excluding cancer, hemiplegic migraine, giant cell arteritis, epilepsy, cerebrovascular disease including TIA, head or neck trauma, altered mental status, personal history of stroke/TIA or cancer, multiple sclerosis, or dementia: 15%				
Lee, 2017 ¹⁸ Y (National) Retrospective Headache and neuropathy Access	2010-2011, vs non-Veterans in non-VA care; Both VA and non-VA: Health Tracking Household Survey	N=203 Self-reported delay in care in last 12 months: M 28.68%, 95% CI 20.18% to 39.0%	N=10,719 Self-reported delay in care in last 12 months: Commercial: M 17.3, 95% CI 16.18% to 18.49%; Medicare: M 17.97 %, 95% CI 13.88% to 22.87%; Medicaid/other: M 15.26%, 95% CI 12.55% to 18.43%	Self-reported delay in care in last 12 months: VA vs commercial: adjusted odds ratio 1.76, 95% CI 1.11 to 2.80, p<0.05	<u>Statistics:</u> Multivariate logistic regression <u>Other methods of controlling:</u> NR <u>Covariates:</u> Perceived general health status, perceived health care satisfaction, age, gender, education, annual family income, race, and region	N	RoB criteria not met: unbalanced samples



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
Axon, 2016 ²³ Y (Regional) Retrospective Heart failure Clinical quality/safety	2007-2011, vs Veterans in non-VA care; CDW vs Medicare inpatient, outpatient, and carrier files	N=2242 Emergency department visits: All cause: M 72.6 SD (79.0); HF-related: M 6.2 SD (22.8); Hospitalizations: All cause: M 31.5 SD (56.7); HF-related: M 6.5 SD (27.1); 30-day readmissions: All cause: M 30.6 SD (54.6); HF-related: M 6.4 SD (27.0)	N=8825 Emergency department visits: All cause: M 45.0 SD (67.5); HF-related: M 3.6 SD (12.6); Hospitalizations: All cause: M 26.0 SD (34.5); HF-related: M 2.8 SD (12.4); 30-day readmissions: All cause: M 23.2 SD (32.4); HF-related: M 2.2 SD (10.2)	Non-VA vs VA Emergency department visits: All cause: adjusted odds ratio (AOR) 0.62, 95% CI 0.60 to 0.64; HF-related: AOR 0.60, 95% CI 0.55 to 0.66; Hospitalizations: All cause: AOR 0.98, 95% CI 0.95 to 1.02; HF-related: AOR 0.61, 95% CI 0.55 to 0.68; 30-day readmissions: All cause: AOR 0.87, 95% CI 0.83 to 0.90; HF-related: AOR 0.51, 95% CI 0.46 to 0.57	<u>Statistics:</u> Zero-inflated negative binomial models <u>Other methods of controlling:</u> NR <u>Covariates:</u> Age, race, gender, year of visit, dual use category, year of visit, and comorbidities that were found to be significant using a stepwise selection procedure	N	P-values not reported; RoB criteria not met: data only from South Carolina
Jia, 2016 ³¹ Y (National) Retrospective Nursing home care Clinical quality/safety	2006-2009, vs Veterans in VA-paid community care; VA MDS 2.0 vs CMS MDS 2.0	N=12,660 Rehabilitation therapy: 75.5%; Restorative nursing care: 33.3%	N=5612 Rehabilitation therapy: 76.4%; Restorative nursing care: 30.6%	VA vs non-VA: Rehabilitation therapy: adjusted odds ratio (AOR) 1.16, 95% CI 1.01 to 1.32, p=0.033; Restorative nursing care: AOR 2.28, 95% CI 2.02 to 2.57, p<0.0001	<u>Statistics:</u> 2-part log-linear model <u>Other methods of controlling:</u> NR <u>Covariates:</u> Gender, education, depression score, ADL score, cognition score, comorbidity index score, number of assessments, facility region, facility rurality, facility hospital status, facility beds, facility resident-to-bed ratio	Y	
Watkins, 2016 ⁴⁰ Y (National) Retrospective Schizophrenia, bipolar disorder, posttraumatic stress disorder, major	FY07-FY08, vs non-Veterans in non-VA care; VA inpatient, laboratory and pharmacy files vs Thomson-Reuters MarketScan Commercial Claims and Encounter Database	N=836,519 Medication laboratory tests: 77.4%; Any laboratory screening tests: 86.9%; Antipsychotics, 12-week supply: 50.0%;	N=545,484 Medication laboratory tests: 5.8%; Any laboratory screening tests: 49.7%; Antipsychotics, 12-week supply: 22.8%;	VA>non-VA for all outcomes, p<0.001	<u>Statistics:</u> NR <u>Other methods of controlling:</u> NR <u>Covariates:</u> Age, gender	Y	



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
depression, and substance use disorders Clinical quality/safety		Maintenance antipsychotics: 37.4%; Maintenance mood stabilizers: 31.3%; Antidepressants, 12- week supply: 49.0%; Maintenance antidepressants: 31.3%	Maintenance antipsychotics: 23.1% Maintenance mood stabilizers: 20.3%; Antidepressants, 12- week supply: 20.2% Maintenance antidepressants: 13.1%				
Jones, 2015 ¹⁴ N (NA) Retrospective analysis of RCT Advanced chronic systolic heart failure Clinical quality/safety	1999, vs non-Veterans in non-VA care; BEST data (VA and non-VA)	N=898 NR	N=1216	VA vs non-VA: All-cause mortality among patients with advanced chronic systolic HF: adjusted odds ratio (AOR) 0.94, 95% CI 0.80 to 1.10, p=0.448; Cardiovascular mortality among patients with advanced chronic systolic HF: AOR 0.92, 95% CI 0.74 to 1.10, p=0.359; HF mortality among patients with advanced chronic systolic HF: AOR 0.76, 95% CI 0.57 to 1.02, p=0.064; Sudden cardiac death among patients with advanced chronic systolic HF: AOR 1.05, 95% CI 0.83 to 1.03, p=0.664; Mortality due to AMI among patients with advanced chronic systolic HF: AOR 3.12, 95% CI 1.19 to 8.19, p=0.021; All-cause hospitalization among patients with	<u>Statistics:</u> Cox proportional hazard models <u>Other methods of controlling:</u> NR <u>Covariates:</u> Age, race, body mass index, smoking, HF duration, coronary artery disease, diabetes mellitus, hypertension, atrial fibrillation, peripheral vascular disease, chronic kidney disease, randomization to bucindolol, use of angiotensin-converting enzyme inhibitors or angiotensin- receptor blockers, digoxin, and diuretics, NYHA class symptoms, LVEF and right ventricular EF (RVEF), cardiothoracic ratio, pulmonary edema, heart rate, systolic and diastolic blood pressure, hemoglobin, serum creatinine, and serum cholesterol	N	RoB criteria not met: clinical trial sample



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
				advanced chronic systolic HF: AOR 0.99 95%, CI 0.88 to 1.10; p=0.868; HF hospitalization among patients with advanced chronic systolic HF: AOR 0.88, 95% CI 0.76 to 1.02, p=0.092			
Chan, 2022 ⁴² Y (National) Retrospective Emergency department care Clinical quality/safety	2001-2018, vs Veterans in non-VA care; CDW and VBA death records vs Medicare claims and SSA death records	N=231,611 30-day mortality after ambulance ride: 9.32 deaths per 100 patients, 95% CI 9.15 to 9.50	N=1,238,546 30-day mortality after ambulance ride: 11.67 deaths per 100 patients, 95% CI 11.58 to 11.76	VA vs non-VA 30-day mortality after ambulance ride: difference -2.35 deaths per 100 patients, 95% CI -2.16 to -2.54	<u>Statistics:</u> Ordinary least squares regression <u>Other methods of controlling:</u> NR <u>Covariates:</u> Zip code of residence, demographic characteristics (age in two year bands, race or ethnic origin, and sex), six binary variables indicating receipt of VA or non- VA primary care, emergency care, and inpatient care in the 12 months before the ride, and previous medical diagnoses, specified as 31 indicators for Elixhauser comorbidities recorded in the 12 months before the ride, origin of the ride (residence; residential, domiciliary, or custodial facility; skilled nursing facility; or scene of accident or acute event), time (day of the week, month- year interactions), life	Y	



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
Florez, 2021 ¹⁵ N (NA) Retrospective analysis of RCT Type 2 diabetes Clinical quality/safety	NR, vs non-Veterans in non-VA care; GRADE data (both VA and non-VA)	N=1216 HbA1c < 7% (<53 mmol/mol) among patients with a history of CVD: 18.1% BP < 140/90 mmHg among patients with a history of CVD: 80.2%; Treated for HTN among patients with a history of CVD: 93.7%; LDLc < 70 mg/dL (1.8 mmol/L) among patients with a history of CVD: 50.0%; LDLc < 100 mg/dL (2.6 mmol/L) among patients with a history of CVD: 81.1%; Statin use among patients with a history of CVD: 87.4%; Aspirin use among patients with a history of CVD: 81.9%; HbA1c < 7% (<53 mmol/mol) among patients with a history of CVD: 15.1%;	N=3831 HbA1c < 7% (<53 mmol/mol) among patients with a history of CVD: 10.9% BP < 140/90 mmHg among patients with a history of CVD: 70.1%; Treated for HTN among patients with a history of CVD: 93.0%; LDLc < 70 mg/dL (1.8 mmol/L) among patients with a history of CVD: 36.9%; LDLc < 100 mg/dL (2.6 mmol/L) among patients with a history of CVD: 74.4%; Statin use among patients with a history of CVD: 84.1%; Aspirin use among patients with a history of CVD: 76.6%; HbA1c < 7% (<53 mmol/mol) among patients with a history of CVD: 14.2%;	VA>non-VA, adjusted analyses BP < 140/90 mmHg among patients with a history of CVD: p=0.035 Treated for HTN among patients with no history of CVD: p=0.006 LDLc < 70 mg/dL (1.8 mmol/L) among patients with no history of CVD: p=0.045 Aspirin use among patients with no history of CVD: p=0.028 HbA1c < 7% (<53 mmol/mol) among patients with no history of CVD: p=0.003	support capabilities, classified according to categories for basic and advanced life support specified in the Healthcare Common Procedure Coding System codes, and primary diagnosis made during the ride, coded according to ICD-9 <u>Statistics:</u> Pearson's chi- squared test with Yates' continuity correction <u>Other methods of controlling:</u> NR <u>Covariates:</u> Age, sex, race, and ethnicity	N	RoB criteria not met: clinical trial sample



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
		BP < 140/90 mmHg among patients with no history of CVD: 73.6%; Treated for HTN among patients with no history of CVD: 74.9%; LDLc < 70 mg/dL (1.8 mmol/L) among patients with no history of CVD: 34.9%; LDLc < 100 mg/dL (2.6 mmol/L) among patients with a history of CVD: 68.2%; Statin use among patients with no history of CVD: Aspirin use among patients with no history of CVD: 70.8%; HbA1c < 7% (<53 mmol/mol) among patients with no history of CVD: 46.6%	BP < 140/90 mmHg among patients with no history of CVD: 76.0%; Treated for HTN among patients with no history of CVD: 65.4%; LDLc < 70 mg/dL (1.8 mmol/L) among patients with no history of CVD: 24.2%; LDLc < 100 mg/dL (2.6 mmol/L) among patients with a history of CVD: 62.9% ; Statin use among patients with no history of CVD: Aspirin use among patients with no history of CVD: 59.5%; HbA1c < 7% (<53 mmol/mol) among patients with no history of CVD: 40.2%				
Feyman, 2022 ⁴⁹ Y (National) Retrospective Primary, specialty, and mental health care Access	2018-2021, vs Veterans in VA-paid community care; CDW (VA and non-VA)	N=4,016,156 Average wait times: Primary care: 29.0 (SD 5.5) days; Mental health care: 33.6 (SD 4.6) days; All other specialties: 35.4 (SD 2.7) days	N=3,042,060 Average wait times: Primary care: 38.9 (SD 8.2) days; Mental health care: 43.9 (SD 9.0) days; All other specialties: 41.9 (SD 5.9) days	Average wait times: Primary care: VA<non-VA in 15 of 18 VISNs; Mental health: VA<non-VA in 16 of 18 VISNs; All other specialties: VA<non-VA in 17 of 18 VISNs	<u>Statistics:</u> Ordinary least squares regressions; 2-sided t-tests <u>Other methods of controlling:</u> NR <u>Covariates:</u> Specialty mix (distribution of stop codes), VISN	Y	
Cashion, 2021 ³⁵ Y (National) Retrospective Post-kidney transplant care	2008-2016, vs Veterans in non-VA care; CDW vs Medicare data	N=752 5-year mortality: 11%	N=2092 5-year mortality: 20%	VA vs non-VA 5-year mortality: adjusted hazard ratio 2.2, 95% CI [1.5, 3.1]	<u>Stats:</u> Multivariable Cox regression <u>Other methods of controlling:</u> NR <u>Covariates:</u> Age at transplantation, sex,	Y	



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
Quality/safety					race, clinical comorbidities, transplant surgery site (within VA versus outside VA via Medicare), year of transplant, prior kidney transplantation, pretransplant dialysis, duration of prior dialysis, and type of transplant (living versus deceased donor)		
Presley, 2022 ²⁵ Y (National) Retrospective Non-small lung cancer Clinical quality/safety	2006-2012, vs non-Veterans in non-VA care; Veterans Central Cancer Registry (VACCR) vs Surveillance, Epidemiology, and End Results (SEER) and Medicare claims	N=18,054 Change in aggressive care at end of life between 2006 and 2012: -15.0% (46.0% to 31.0%)	N=13,277 Change in aggressive care at end of life between 2006 and 2012: -3.8% (41.9% to 38.0%)	Change in aggressive care at end of life between 2006 and 2012: VA>non-VA, p<0.001; % change in hospice admissions in Medicare hospital referral region on aggressive care at matched VA facility: AOR 0.13, 95% CI 0.08 to 0.23	<u>Statistics:</u> Chi-square tests <u>Other methods of controlling:</u> NR <u>Covariates:</u> Age, sex, race, comorbidities	N	No adjustment for demographic covariates in main analysis; composition of multicomponent aggressive care measure unclear
Pickering, 2022 ⁵⁴ Y (National) Retrospective Low-value prostate-specific antigen (PSA) testing Cost/efficiency	FY2017-FY2018, vs Veterans in non-VA care; CDW, Area Resource File, and VHA Service Support Center vs Beneficiary Summary File, Medicare Provider Analysis and Review, Inpatient, Skilled Nursing Facility, Outpatient, Home Health Agency, Hospice, Durable Medical Equipment, and Carrier files	N=36,469 Total downstream or "cascade" services related to low-value PSA testing: 53.9 services/100 Veterans; Cost of cascade services related to low-value PSA testing: \$45.1/Veteran	N=17,981 Total downstream or "cascade" services related to low-value PSA testing: 45.3 services/100 Veterans; Cost of cascade services related to low-value PSA testing: \$35.0/Veteran	Non-VA vs VA Adjusted difference in downstream or "cascade" services related to low-value PSA testing: 9.9 services/100 Veterans, 95% CI 9.7 to 10.1; Adjusted cost of cascade services related to low-value PSA testing: \$11.9/Veteran, 95% CI \$7.6 to \$16.2	<u>Statistics:</u> Negative binomial models; weighted linear regression <u>Other methods of controlling:</u> Stabilized inverse probability of treatment weights <u>Covariates:</u> Age, race and ethnicity, VA priority group, driving distance to the nearest VA facility, number of Elixhauser conditions, individual Elixhauser conditions, academic affiliation, facility size,	Y	



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
					census region, rurality, and complexity level at the VA medical center-level		
Fortney, 2022 ¹⁹ N (NA) Prospective survey In-person- and tele- mental health care Access Cost/efficiency Patient experience Clinical quality/safety	2019-2020, vs Veterans in VA-paid community care; CDW and telephone survey	N=303 Number of barriers to care: M 0.9, SD 1.3; Number of encounters: M 5.9, SD 7.3; Patient centeredness: M 4.3, SD 0.6; Change in PHQ-8 (depression symptoms): M -1.2, SD -4.9; Change in PCL-5 (post- traumatic stress disorder symptoms): M -3.4, SD -12.5	N=242 Number of barriers to care: M 1.3, SD 1.6; Number of encounters: M 6.2, SD 6.8; Patient centeredness: M 4.2, SD 0.7; Change in PHQ-8 (depression symptoms): M -2.2, SD -5.3; Change in PCL-5 (post- traumatic stress disorder symptoms): M -6.0, SD -12.6	Number of access- related barriers to care: VA<non-VA: p<0.001; Number of encounters: VA=non-VA: p=0.276; Patient centeredness: VA=non-VA: p=0.243; Change in PHQ-8 (depression symptoms): VA>non-VA: p=0.011; Change in PCL-5 (post- traumatic stress disorder symptoms): VA=non-VA: p=0.148	<u>Statistics:</u> Multivariate statistical analyses; chi-square and t-tests <u>Other methods of controlling:</u> NR <u>Covariates:</u> Provisional diagnosis, suicidality, rurality, and prior VA mental health use	N	Small sample size
Scheuner, 2022 ⁴⁴ Y (National) Retrospective Genetic counseling Clinical quality/safety	2010-2017, vs Veterans in VA-paid community care; CDW	N=6775 Genetic referrals completed (% of total referrals): 5073 (74.9%)	N=3423 Genetic referrals completed (% of total referrals): 1961 (57.3%)	Non-VA vs VA: Completed genetic consultations: OR 0.43, 95% CI 0.28 to 0.65; Follow-up cancer surveillance and risk- reducing procedures among those who completed a genetic consultation: OR 0.64, 95% CI 0.52 to 0.78	<u>Statistics:</u> Multivariate regression models <u>Other methods of controlling:</u> NR <u>Covariates:</u> Genetic referral models: care model x age, x race or ethnicity, and x gender interactions; Risk- reducing surveillance/ procedures models: care model x consultation status interactions, and cardiovascular disease	Y	
Petros, 2022 ²⁰ Y (Local) Retrospective Colorectal cancer Clinical quality/safety Access	2015-2018, vs Veterans in VA-paid, community care; Chart review	N=235 Adenomas detection (adenoma detection rate): 147 (62.6%);	N=235 Adenomas detection (adenoma detection rate): 86 (36.7%);	Non-VA vs VA: Adenoma detection rate: OR 0.39, 95% CI 0.25 to 0.63; Compliance with surveillance guidelines:	<u>Statistics:</u> Multivariate logistic regression <u>Other methods of controlling:</u> NR <u>Covariates:</u> (Adenoma model) Diabetes mellitus, preparation	N	Small sample size; only one facility sample; no demographic controls in statistical models



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
		Compliance with surveillance guidelines: 93.3%; Time to colonoscopy: M 83.8 days, 95% CI 45.2 to 122.4 days	Compliance with surveillance guidelines: 74.9%; Time to colonoscopy: M 58.4 days, 95% CI 24.7 to 92.1 days	OR 0.21, 95% CI 0.09 to 0.45; Time to colonoscopy: non-VA<VA, p<0.0001	quality adequate, and cecal intubation; (Guideline model) adenoma detected, performed by non-gastroenterologist, screening indication, surveillance indication, and adequate bowel preparation		
Weeda, 2023 Y (National) Retrospective Acute myocardial infarction Clinical quality/safety	2013-2018, vs Veterans in non-VA care; CDW vs CMS data (inpatient, outpatient, and pharmacy claims from parts A, B, and D)	N=16,247 Any medication class omitted: 67.8% All medication classes omitted: 9.5% ACEI/ARB omission: 45.5% Beta-blocker omission: 23.7% Statin omission: 22.6% High-intensity statin omission: 41.2% P2Y12 inhibitor omission: 38.3%	N=102,209 Any medication class omitted: 82.8% All medication classes omitted: 29.8% ACEI/ARB omission: 62.8% Beta-blocker omission: 47.4% Statin omission: 45.5% High-intensity statin omission: 72.1% P2Y12 inhibitor omission: 59.8%	Non-VA vs. VA: Any medication class omitted: OR 3.04 (95% CI 2.88, 3.20) All medication classes omitted: OR 4.21 (95% CI 3.95, 4.49)	<u>Statistics:</u> Generalized linear models with a logit link <u>Other methods of controlling:</u> Models were built in a sequential manner using all available covariates after checking for multicollinearity. Model fit was assessed through residual analysis. <u>Covariates:</u> Demographic variables, service-related disability percentage, primary care utilization rates, pre-MI secondary prevention medication use, smoking status, and all comorbidities	Y	
Gaffney, 2022 Y (National) Retrospective Influenza vaccination Equity	2019-2020, vs Veterans in non-VA care & non-Veterans in non-VA care; National Health Interview Survey	N=2821 Influenza vaccination rate: 63.0%	N=46,456 Non-VA Veterans, Influenza vaccination rate: 59.1%	Influenza vaccination rates: Non-Veterans vs. VA: Black (vs. white): -6.9% (95% CI -15.2% to 1.4%)	<u>Statistics:</u> Logistic regressions; predicted probabilities <u>Other methods of controlling:</u> NR	N	Self-reported vaccination status



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
			Non-VA, non-Veterans, Influenza vaccination rate: 46.5%	Hispanic (vs. white): -18.4% (95% CI -29.9% to -7.0%) Other race (vs. white): 5.4% (95% CI -7.6% to 18.3%) Middle-income vs. low- income: -6.7% (95% CI - 13.2% to -0.1%) High-income vs. low- income: -8.5% (95% CI - 15.6% to -1.4%) Veterans in non-VA care vs. VA: Black (vs. white): -5.6% (95% CI -22.1% to 10.9%) Hispanic (vs. white): -3.7% (95% CI -14.9% to 7.6%) Other race (vs. white): - 8.5 (95% CI -26.2% to 9.2%) Middle-income vs. low- income: -4.4% (95% CI - 12.9% to 4.0%) High-income vs. low- income: -8.0% (95% CI - 16.7% to 0.9%)	<u>Covariates:</u> Race/ethnicity, veteran/VA indicator, an interaction term for veteran/VA indicator, age, sex, self-reported health status, family income; family income and race covariates were used in separate models		
Ramanathan, 2023 Y (National) Retrospective Antibiotic prophylaxis for dental procedures Clinical quality/safety	2015-2017, vs non- Veterans in non-VA care; CDW vs Marketscan data	N=18,292 Guideline concordant antibiotic prescribing: 30.9%	N=42,832 Guideline concordant antibiotic prescribing: 33.5%	VA vs non-VA: Guideline concordant antibiotic prescribing: OR 1.21 (95% CI 1.16 to 1.25) Guideline concordant antibiotic prescribing without prosthetic joint:	<u>Statistics:</u> Multivariable log binomial regression analyses or Poisson regressions <u>Other methods of controlling:</u> Backward selection, Akaike Information Criterion (AIC) for covariate selection	N	Use of Marketscan claims data



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
				OR 0.99 (95% CI 0.96 to 1.01) Guideline concordant antibiotic prescribing with prosthetic joint: OR 1.73 (95% CI 1.59 to 1.88) Guideline concordant antibiotic dosing based on antibiotic duration: OR 1.11 (95% CI 1.07 to 1.15)	<u>Covariates:</u> Age, sex, prosthetic joint, region, urban/rural, Charlson score, dental service category		
Ohl, 2023 Y (National) Retrospective Deaths and readmissions during the COVID-19 pandemic Clinical quality/safety	2020-2021, vs. Veterans in VA-paid and non-VA-paid community care; CDW, VHA Program Integrity Tool, CMS enrollment and claims, AHA survey, CDC Agency for Toxic Substances and Disease Registry Social Vulnerability Index	N=17,035 30-day mortality: 3021 (17.7%) 30-day readmissions: 2006/14,357 (14.0%)	N=47,821 30-day mortality: 12,951 (27.1%) 30-day readmissions: 4898/38,576 (12.7%)	Non-VA vs. VA: 30-day mortality: OR 1.37 (95% CI 1.21 to 1.55) 30-day readmissions: OR 0.89 (95% CI 0.86 to 0.92) Non-VA CC vs. VA: 30-day mortality: OR 1.44 (95% CI 1.26 to 1.64) 30-day readmissions: OR 0.91 (95% CI 0.81 to 1.01)	<u>Statistics:</u> Logistic regressions <u>Other methods of controlling:</u> Inverse probability of treatment weights, propensity scores <u>Covariates:</u> Patient age, race and ethnicity, sex, rural residence, Social Vulnerability Index, date of admission, distance to nearest VHA hospital, distance to nearest community hospital, comorbidities, acuity	Y	
Yoon 2023 Y (National) Retrospective Hospital discharges for acute myocardial infarction, gastrointestinal hemorrhage, heart failure, pneumonia, stroke	2012-2017, vs. Veterans in non-VA care VA Managerial Cost Accounting files State-wide all-payer discharge data in 11 states	N=96450 30-day mortality (65 and over only): AMI: 9.8% GI bleed: 4.1% HF: 6.0% Pneumonia: 7.2% Stroke: 7.0%	N=418273 30-day mortality (65 and over only): AMI: 12.0% GI bleed: 5.8% HF: 10.4% Pneumonia: 9.7% Stroke: 16.5%	VA compared to nonVA care in adjusted models for 30-day mortality (65 and over): AMI:0.012 GI bleed: 0.004 HF: -0.017 Pneumonia: -0.004 Stroke: -0.053 Bold = p<0.05	<u>Statistics:</u> Inverse probability weighted regression adjustment <u>Other methods of controlling:</u> N/A <u>Covariates:</u> age, sex, race, ethnicity, marital status, priority for VA care, comorbidity score, comorbidity for SUD or PTSD, geographic region, and	Y	Outcomes also reported for age <65



Author Year Large Database (Y/N) Study Design Medical Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
					post-CHOICE act period		
Wachterman 2024 N (National) Retrospective End-of-life care	2021-2022, vs. Veterans in VA-paid community care VA Bereaved Family Survey to measures the quality of end-of-life care, stratified by VA CLC or CA- contracted community nursing homes	N=1012 Overall rating of EOL care as 9/10: 84.8%	N=226 Overall rating of EOL care as 9/10: 71.2%	Adjusted odds ratio of overall better care at VA CLC = 2.35, 95% CI 1.68-3.29	<u>Statistics: Logistic regression using "top box" (9/10) as outcome</u> <u>Other methods of controlling: N/A</u> <u>Covariates: Age, sex, race/ethnicity, next-of- kin relationship and education, length of hospice stay</u>	N	Based on family response to survey, which only 41% (for VA) and 21% (for community nursing homes) were completed
Wadhwa 2024 Y (Local) Retrospective Prostate cancer outcomes in California	2000-2018, vs. non- Veterans VA Central Cancer Registry California Cancer Registry	N=1881 44.3% Black	N=47580 17.2% Black	!0-year all-cause survival was worse in Black patients treated in the community (p<0.01), whereas there was no evidence of racial disparities in the VA cohort	<u>Statistics: Kaplan- Meier analysis for all- cause survival, logistic regression, and Cox proportional hazards models</u> <u>Other methods of controlling: N/A</u> <u>Covariates: Age at diagnosis, ethnicity, year of diagnosis, socioeconomic status, stage at diagnosis, census-tract-level population density</u>	Y	



SURGICAL CARE

Author Year Large Database (Y/N) Study Design Health Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
George, 2021 ⁶ Y (National) Retrospective Noncardiac surgery	2015-2018, vs other non-VA VASQIP vs NSQIP	N: 736477 30-day mortality: 8008 (1.1%) 30-day complications: 125816 (17.1%) Failure to rescue: 5918 (4.7%)	N: 3174274 (NSQIP) 30-day mortality: 2602 (0.8%) 30-day complications: 299984 (9.5%) Failure to rescue: 19936 (6.7%)	VA vs NSQIP 30-day mortality: RR(adj)=0.59 (95% CI: 0.47-0.75), p<0.001 Failure to rescue (with complications): RR=0.55 (95% CI: 0.44-0.68) (reference group: gen pop)	<u>Stats:</u> Multivariate log binomial regression <u>Other methods of controlling:</u> Serial modeling with subgroup analysis for 30-day mortality <u>Covariates:</u> age, sex, race/ethnicity, oss, rai, emergency/elective, postoperative complication	Y	Also performed sensitivity analyses with frailty and urgency (not abstracted)
George, 2024 ⁷ Y (National) Retrospective Noncardiac surgery in women	2016-2019, vs other non-VA VASQIP vs NSQIP	N: 36478 procedures 30-day mortality: 0.1% 30-day complications: 3.4% Failure to Rescue: 0.1%	N: 1727062 procedures 30-day mortality: 0.3% 30-day complications: 3.7% Failure to Rescue: 0.2%	VA vs NSQIP 30-day mortality: RR(adj)=0.41 (95% CI: 0.23-0.76), p<0.001 Failure to rescue (with complications): RR=0.41 (95% CI: 0.18-0.92)	<u>Stats:</u> Multivariate poisson regression <u>Other methods of controlling:</u> Coarsened matching to balance groups <u>Covariates:</u> frailty, race/ethnicity, operative stress score, elective/urgent	Y	Also performed sensitivity analyses on surgery type and frailty
Simmonds, 2024 ⁵ Y (National) Retrospective Colectomy	2015-2019, vs other non-VA VASQIP vs NSQIP	N: 11115 procedures 30-day mortality: 1.4% Any complication: 18% Return to OR: 7.1% Surgical site infection: 3.4% Wound dehiscence: 1.6% Post-operative pneumonia: 1.4% Pulm embolism: 0.7% Cardiac arrest: 0.7% Sepsis: 3.0%	N: 235097 procedures 30-day mortality: 1.2% Any complication: 22% Return to OR: 4.6% Surgical site infection: 3.6% Wound dehiscence: 0.9% Post-operative pneumonia: 1.9% Pulm embolism: 0.5% Cardiac arrest: 0.4% Sepsis: 0.7%	VA vs NSQIP after excluding emergency cases 1.2% vs 1.4% p=0.145 Any complication: 17.7% vs 22%, p<0.001	<u>Stats:</u> multivariate logistic regression <u>Covariates:</u> age, sex, body mass index, functional status, emergency designation, ASA class, steroid usage, preoperative sepsis, smoking status, and presence of several chronic conditions	Y	Sensitivity analysis on open vs. laparoscopic cases showed more variability in open cases Data extracted for cohort that excluded emergency cases
Buys, 2024 ⁴ Y	2018-2021, vs VA-paid community care	N: 239	N: 323	Adjusted odds of receiving fewer opioid	<u>Stats:</u> binomial regression model	Y	



Author Year Large Database (Y/N) Study Design Health Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
Retrospective Orthopedic joint surgery	Corporate data warehouse and medical records	Median of 30 opioid tablets prescribed on discharge	Median of 40 opioid tablets prescribed on discharge	tablets in the first 90 days 0.45, p<0.001	<u>Covariates:</u> age, sex, BMI, rural residence, number of days in hospital before surgery, surgery type, any mental health diagnosis, any substance use disorder		
Yoon, 2023 ² Y Retrospective CABG	2012-2017 VA Managerial Cost Accounting files State-wide all-payer discharge data in 11 states	N:2548 30-day mortality(>65 years of age) 2.1% LOS (>65 years of age) 11.7 days Cost (>65 years of age) \$76,200	N:15981 30-day mortality(>65 years of age) 2.2% LOS (>65 years of age) 9.6 days Cost (>65 years of age) \$53,100	Average treatment outcome (>65 years of age) 30-d mortality 0.009 p=0.17 30-d readmission (>65 years of age) -0.045, p<0.001	<u>Stats:</u> inverse probability weighted regression adjustment <u>Covariates:</u> age, sex, race, ethnicity, marital status, priority for VA care, comorbidity score, comorbidity for SUD or PTSD, geographic region, and post-CHOICE act period	Y	Outcomes also reported for age <65
Heiden, 2021 ⁶⁸ Y (National) Retrospective Lung resection	2006-2016 (vs other non- VA: NCDB) VA CDW vs NCDB	N: 6792 Length of stay: 8.12 days (SD 6.59) 30-day readmissions: 523 (7.70%) 30-day mortality: 128 (1.9%) 90-day mortality: 250 (3.7%) Median overall survival: 71.4 months	N: 6792 (NCDB) Length of stay: 7.08 days (SD 7.54) 30-day readmissions: 470 (7.02%) 30-day mortality: 188 (2.8%) 90-day mortality: 331 (5.0) Median overall survival: 65.2 months	<u>Unadjusted/matched</u> <u>cohort:</u> Length of stay: p<0.001 30-day readmissions: p=0.132 Median overall survival: p<0.001 30-day mortality: p<0.001 90-day mortality: p<0.001 Median overall survival, VA vs NCDB: p=0.0006	<u>Stats:</u> Kaplan-Meier with log-rank tests <u>Other methods of</u> <u>controlling: propensity</u> <u>score matching</u> <u>Covariates:</u> age, sex, race, income, educational level, Charlson/Deyo score, distance to hospital, tumor size, year of diagnosis	Y	
Blay, 2017 ³⁶ Y (National) Retrospective Hospital PSI	2012-2015, vs other non- VA Hospital Compare	N: 129 hospitals Death among surg inpatients w/ treatable conditions: 105.82 per 1000 discharges Postoperative sepsis: 7.52 per 1000 discharges Postoperative wound	N: 4010 hospitals Death: 136.34 per 1000 discharges Postoperative sepsis: 10.22 per 1000 discharges Postoperative wound dehiscence: 2.32 per	Death: VA 95% CI 96.7- 114.92; non-VA 95% CI 135.42-137.26 (P<0.05 with Bonferroni correction) Postoperative sepsis: VA 95% CI 6.10-8.95; non-VA 95% CI 10.12-	<u>Stats:</u> t tests with and without Bonferroni correction for multiple comparisons to evaluate pairwise comparisons between VA and non-VA hospitals for risk-	Y	Hospital level data. Subgroups of only medical reasons for death and readmissions were not



Author Year Large Database (Y/N) Study Design Health Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
		dehiscence: 2.17 per 1000 discharges VTE: 3.94 per 1000 discharges	1000 discharges VTE: 5.08 per 1000 discharges	10.32 (P<0.05 with Bonferroni correction) Postoperative wound dehiscence: VA 95% CI 1.64-2.71; non-VA 95% CI 2.30-2.33 VTE: VA 95% CI 3.42-4.45; non-VA 95% CI 5.00-5.15	adjusted rates of outcome measures <u>Other methods of controlling:</u> N/A <u>Covariates:</u> N/A		collected
Eid, 2020 ⁶⁶ N (National) Retrospective Surgery PSI/satisfaction	2018, vs other non-VA Hospital Compare	N: 34 hospitals DVT/PE: 3.56 per 1000 patients Wound dehiscence: 0.29 per 1000 patients Postoperative mortality: 95 per 1000 patients Surgical-specific patient safety indicator: 18.0 per 1000 patients Compiled patient satisfaction star ratings: 2.96 Recommended hospital rating 2.7	N: 319 hospitals DVT/PE: 4.05 per 1000 patients Wound dehiscence: 0.83 per 1000 patients Postoperative mortality: 167 per 1000 patients Surgical-specific patient safety indicator: 51.4 per 1000 patients Patient satisfaction star ratings: 2.97 recommended hospital rating 3.13	DVT/PE: p= 0.18 Wound dehiscence: p<0.01 Postoperative mortality: p<0.001 Surgical-specific patient safety indicator: p<0.001 Patient satisfaction star ratings: p=0.9 Recommended hospital rating: p= 0.007	<u>Stats:</u> paired-sample t-test <u>Other methods of controlling:</u> N/A <u>Covariates:</u> N/A	N (relative to Blay fewer hospital and fewer years	
Harris, 2021 ⁶⁹ Y (National) retrospective cohort Elective TKA	VA: 2017-2019 vs Veteran in non-VA ("VA-purchased") CDW/ Medicare vs CDW/ Medicare	N: 24,407 Any complication: 712 (2.9%) MI: 45(0.2%) Joint/wound infection: 236 (1.0%) Pneumonia: 129 (0.5%) PE: 193 (0.8%)	N: 18,964 Any complication: 611 (3.2%) MI: 92 (0.5%) Joint/wound infection: 128 (0.7%) Pneumonia: 140 (0.7%) PE: 109 (0.6%)	adjusted odds ratios (reference group: CC): Any complication: 0.45 (95% CI: 0.38, 0.54) MI: 0.21 (p<0.001, CIs not reported) Joint/wound infection: 0.69 (p<0.001) Pneumonia 0.34 (p<0.001) PE 0.73 (p<0.01) (reference group: CC)	<u>Stats:</u> mixed-effects logistic regression (random effects for patients, setting, and VA facility) <u>Covariates:</u> age, sex, race, marital status, rurality, priority level (service connected disability/income level), Nosos risk score	Y	Full sample (not the 30-30 volume based sample) used to data abstract. <i>Reason for map being "mixed". National level data show VA better but 5 individual VA facilities (supplement S7) had worse complications</i>
Rosen A, 2021 ⁷⁰ Y (National)	2014-2015, VA vs vets in non-VA ("CC") CDW	N: 44546 30-day complication for complex surgeries in all	N: 17203 30-day complication for complex surgeries in all	30-day complication for complex surgeries in all eyes: RR(unadj)=0.94	<u>Stats:</u> Firth's penalized maximum likelihood logistic regression	Y	Did not abstract low- and high-



Author Year Large Database (Y/N) Study Design Health Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
Retrospective Cataract surgery		eyes: 164 (1.61%) 30-day complication for routine surgeries in all eyes: 313 (0.65%) 90-day complication for complex surgeries in all eyes: 228 (2.24%) 90-day complication for routine surgeries in all eyes: 476 (0.99%)	eyes: 58 (1.52%) 30-day complication for routine surgeries in all eyes: 131 (0.59%) 90-day complication for complex surgeries in all eyes: 81 (2.13%) 90-day complication for routine surgeries in all eyes: 195 (0.89%)	(95% CI: 0.70, 1.27); AR=-0.09 (95% CI: -0.56, 0.38) 30-day complication for routine surgeries in all eyes: RR(unadj)=0.91 (95% CI: 0.74, 1.16); AR=-0.06 (95% CI: -0.19, 0.07) 90-day complication for complex surgeries in all eyes: RR(unadj)=0.95 (95% CI: 0.74, 1.22); AR=-0.12 (95% CI: -0.66, 0.43) 90-day complication for routine surgeries in all eyes: RR(unadj)=0.89 (95% CI: 0.75, 1.05); AR=-0.11 (95% CI: -0.26, 0.05) (Reference group: VA) 90-day complication (CC vs VA): OR(adj)=0.918 (95% CI: 0.765-1.097), p=0.349	<u>Other methods of controlling:</u> N/A <u>Covariates:</u> community care status, complex surgery, eye risk group, complex surgery*CC, complex surgery*high-risk eye, CC*high-risk eye, complex surgery*CC*high-risk eye, demographic variables (i.e., rural status, race, number of preoperative ocular conditions)		risk eyes subgroups
Rosen, 2021 ⁵⁶ Y (National) Retrospective TKA	2016-2019, VA vs vets in non-VA ("CC") CDW and Medicare data	N: 25,384 All-cause readmission rate: 4.3% TKA-related readmission rate: 1.3%	N: 19,990 All-cause readmission rate: 4.6% TKA-related readmission rate: 1.2%	adjusted odds ratio (reference: CC) all-cause readmissions: OR=0.35 (95% CI: 0.30-0.40) TKA-related readmissions: OR=0.30 (95% CI: 0.23-0.38)	<u>Stats:</u> mixed effects logistic regression (fixed effects for setting, random effects for VA facility and setting) <u>Covariates:</u> gender, age, race, marital status, rurality, Medicaid insurance, priority level, Nosos risk score	Y	Used the data that included Medicare data (did not use analysis that removed medicare) did not abstract individual facility level OR (finding: 1 VA facility had sig higher odds of all-cause readmits than paired CC; 3 VA facilities had sig



Author Year Large Database (Y/N) Study Design Health Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
Williams, 2020 ⁶⁰ Y (National) Retrospective Lung resection	2001-2009, vs other non-VA VA CDW vs SEER-Medicare	N: 7895 Black vs White overall 5-year survival: no raw event data Black vs White lung cancer-specific 5-year survival: no raw event data Overall treatment type: <i>None</i> : 1930 (24.5%) <i>Surgery only</i> : 3648 (46.2%) <i>RT only</i> : 1446 (18.3%) <i>Chemo only</i> : 181 (2.3%) <i>>1 treatment</i> : 690 (8.7%)	N: 8744 (Seer-Medicare) Black vs White overall 5-year survival: no raw event data Black vs White lung cancer-specific 5-year survival: no raw event data Overall treatment type: <i>None</i> : 1412 (16.2%) <i>Surgery only</i> : 4454 (50.9%) <i>RT only</i> : 978 (11.2%) <i>Chemo only</i> : 171 (2.0%) <i>>1 treatment</i> : 1729 (19.8%)	Black vs White overall 5-year survival: VA cohort HR(adj)=1.08 (95% CI: 1.00-1.16), P=0.041; SM cohort HR(adj)=1.17 (95% CI: 1.06-1.30), P<0.0001 Black vs White lung cancer-specific 5-year survival: VA cohort HR(adj)=1.06 (95% CI: 0.96-1.17), P=0.26; SM cohort HR(adj)=1.21 (95% CI: 1.07-1.37), P<0.0001 Unadjusted overall treatment type: p<0.01 for VA and SM Blacks vs White surgery only treatment group: VA cohort OR(adj)=0.73 (95% CI: 0.62-0.86); SM cohort OR(adj)=0.57 (95% CI: 0.47-0.70)	<u>Stats</u> : multinomial logistic regression for odds of treatment type; univariate Kaplan-Meier for survival, White/Black groups compared by log-rank test. <u>Other methods of controlling</u> : N/A <u>Covariates</u> : age at diagnosis, marital status, Charlson comorbidity score, histology stage, year of diagnosis	Y	higher odds TKA-related readmit vs paired CC)--thus mixed findings Findings confirmed by multivariate (less difference between Black and White in VA compared with non-VA)
Kesseli, 2020 ⁶¹ Y (National) Retrospective Kidney transplant	2001-2016, SRTR (vs other non-VA)	N: 1508 transplants report observed number / expected number (O:E ratio) 1-year graft survival: 78/97.8 (0.79) 1-month mortality: 3/11.3 (0.26) 1-year mortality: 33/53.6 (0.57) N: 617 transplants 3-year graft loss: O:E = 0.88 (95% CI 0.69-1.09)	N: 227,680 transplants 1-year graft survival: 14,185/14,149 (1.00) 1-month mortality: 1348/1340 (1.01) 1-year mortality: 6190/6174 (1.00) N: 74,478 transplants 3-year graft survival: O:E = 1.00 (95% CI: 0.98-1.02)	1-year graft survival: O:E= 0.79 (95% CI 0.63-0.98) vs 1.00 (0.98-1.02), P = 0.15 1-month mortality: O:E = 0.27 (0.05-0.65) VA vs 1.00 (0.95-1.06) non-VA, P = 0.03 1-year mortality: O:E = 0.62 (0.42-0.84) VA vs 1.00 (0.98-1.03) non-VA, P = 0.03 3-year graft survival: p=0.46	<u>Stats</u> : observed vs expected ratios. Expected probabilities calculated from Scientific Registry of Transplant Recipients using Cox proportional hazard model from national data (includes 33 patient, donor, and transplant characteristics)	Y	Abstracted data for VA and non-VA sites (did not include VA-affiliate sites) given all data reported in paper, reporting as equal/mixed (abstracted data shows mostly VA better)



Author Year Large Database (Y/N) Study Design Health Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
Barnett, 2018 ²⁶ Y (National) Retrospective CABG	2014 - 2017, Veterans in VA vs Veterans not in VA ("CC") ?data source: ?CDW vs CC claims	N: 4866 Actual distance traveled: 123.2 miles 30-day mortality: 1.50% (77 deaths) 30-day readmission: 7.12% (346 readmissions) Total cost (no unadjusted data)	N: 952 Actual distance traveled: 81.5 miles 30-day mortality: 1.26% (12 deaths) 30-day readmission: 8.25% (79 readmissions) Total cost (no unadjusted data)	Actual travel distance: p=0.02 Unadjusted 30d mortality: p=0.57 Adjusted 30d mortality: 1.51% for VA vs 1.33% for CC (p=0.74); RR (adj)=0.89 (95% CI: 0.45-1.77) Adjusted 30-day readmission: 7.00% for VA vs 8.13% for CC (p=0.28); RR (adj)=1.16 (95% CI: 0.89-1.50) Mean adjusted total cost: \$65264 (SD: \$47978) for VA vs \$56749 (SD: \$77283) for CC (p<0.01) [adjusted: CC is reference]	<u>Stats:</u> log binomial models for mortality and readmission, log gamma models for costs <u>Other methods of controlling: propensity weighting</u> to control for differences in case mix between VA and CC patients <u>Covariates (in propensity adjustment):</u> age, sex, race/ethnicity, recent myocardial infarction, prior PCI, prior CABG surgery, cerebrovascular disease, peripheral vascular disease, congestive heart failure, Type 1 diabetes, Type 2 diabetes, body mass index, renal function, dialysis, chronic obstructive pulmonary disease, atrial fibrillation, number of vessels revascularized	Y	Did not abstract PCI data Travel data: reported only actual distance traveled Costs: total cost (Table 3), which is different from mean-adjusted index cost Mortality: reporting figure 1 adjusted at patient (not hospital) level factors
Frisch, 2020 ⁵⁷ Y (National) Retrospective Elective THA	2014 (vs other non-VA) CDW vs NSQIP	N: 10460 Length of stay 4 days or greater: 4805 (47%) 30-day complications: 908 (9%) PE: 74 (0.7%) MI: 39 (0.4%) DVT: 152 (1.5%) Pneumonia: 82 (0.8%) Post-operative infection: 220 (2%)	N: 58820 (NSQIP) Length of stay 4 days or greater: 9815 (17%) 30-day complications: 1608 (3%) PE: 308 (0.5%) MI: 121 (0.2%) DVT: 414 (0.7%) Pneumonia: 10 (<0.1%) Post-operative infection: 619 (1%)	OR(adj) for LOS >3d (VA vs non-VA) =4.46 (95% CI: 4.21-4.72) OR(adj) for 30-d complications (VA vs non-VA) =2.58 (95% CI: 2.31-2.89) OR(adj) for 30-day readmissions (VA vs non-VA)=4.94 (95% CI: 4.51-5.41) Unadjusted length of	<u>Stats:</u> multivariate logistic regression <u>Other methods of controlling:</u> N/A <u>Covariates:</u> sex, age, race, BMI, diabetes mellitus, chronic obstructive pulmonary disease, chronic kidney disease, metastatic cancer,	Y	Reported OR(adj) for length of stay greater than 3 days rather than 4 days because missing latter analysis



Author Year Large Database (Y/N) Study Design Health Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
		30-day readmissions: 1773 (17%)	30-day readmissions: 1955 (3%)	stay 4 days or greater: p<0.001 Unadjusted 30-day complications: p<0.001 Unadjusted 30-day readmissions: p<0.001 Unadjusted PE: p=0.019 Unadjusted MI: p=0.001 Unadjusted DVT: p<0.001 Unadjusted pneumonia: p<0.001 Unadjusted post- operative infection: p<0.001 (Reference for adjusted measurements: non-VA)	hypertension, congestive heart failure		
Hutt, 2015 ⁵⁹ N (National) Retrospective Hip fracture repair	2003-2005 VA vs other non-VA VA NSQIP vs Medicare	N: 947 Avg days from admission to surgery: 5.64 (SD 43.25) Survival at 30-days: 89.65% Survival at 1yr: 63.04%	N: 947 (Medicare) Avg days from admission to surgery: 1.78 (SD 2.35) Survival at 30-days: 92.93% Survival at 1yr: 70.43%	<u>Unadjusted/matched cohort:</u> Avg days from admission to surgery: p=.0063 Survival at 30-days: p=0.0106 Survival at 1 year: p=0.0006 30-day survival odds (Medicare vs VA) OR :1.701 (95% CI: 1.184- 2.445) (p<0.001) 1 year survival odds (Medicare vs VA) OR :1.504 (95% CI: 1.208- 1.872) (p<0.001)	<u>Stats:</u> Multivariate logistic regression <u>Other methods of controlling: Propensity matching</u> <u>Covariates:</u> propensity matching: age, sex, race, prehospital location, type of surgery, comorbidities, region, year of surgery, primary diagnosis; odds of survival using matched cohort: year of surgery, number of hospital days before/after surgery, chronic conditions	Y	Large dot because N=947 per group in the propensity matched sample, used VASQIP and Medicare data)
Griffith, 2020 ⁴⁸ Y (National) Retrospective Ortho/Urology wait times	2013-2019 vs 2018-2019 (vs Vets in non-VA)	N: 506945 (orthopedics), 353029 (urology) Mean wait time for orthopedics: 36.2 days (SD 9.3) Mean wait time for urology: 36.1 days (SD 9.5)	N: 139827 (orthopedics), 37089 (urology) Mean wait time for orthopedics: 43.6 days (SD 12.9) Mean wait time for	orthopedics (r=0.50) urology (r=0.30)	<u>Stats:</u> mean appointment wait times; Weighted Pearson correlation coefficients between VHA and CC wait times <u>Other methods of</u>	Y	



Author Year Large Database (Y/N) Study Design Health Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
			urology: 50.5 days (SD 14.5)		<u>controlling:</u> N/A <u>Covariates:</u> N/A		
Billig, 2021 ⁶⁴ N (National) Retrospective Carpal tunnel	2010-2015 (vs Veteran in non-VA) CDW data	N: 23330 Median Referral PCP to CTR days: 176 days IQR: 94-470)	N: 5912 (mixed care) Median Referral PCP to CTR days: 378 days (IQR: 136-1136)	Median Referral PCP to CTR days (VA vs mixed care): HR(unadj)=0.63 (95% CI: 0.61-0.64); HR(adj)=0.63 (95% CI: 0.61-0.65)	<u>Stats:</u> Multivariable cox proportional hazard models; kaplan meier with log-rank comparisons <u>Other methods of controlling:</u> Controlling for other services received in community <u>Covariates:</u> age, sex, race, CCI, diabetes, VA priority group, PCP facility type, PCP and surgical specialist located within same facility, proportion of patients referred for any community care for a CTS-related service at the facility level	N (mixed care group was not uniform)	Note: comparison group is people with some portion of their diagnostic workup, nonsurgical or surgical care being in community, compared to entire workup/ treatment in VA. Likely some bias with some VA surgeries occurring in the mixed comparison group, thus small circle.
Pettey, 2021 ⁶⁵ Y (National) retrospective Cataract	FY2015 (vs vets in non-VA "CC")	N: 58050 cataract procedures Median driving miles to closest VA facility: 28.1 (SD 39.2) Median driving miles to actual VA facility: 31.2 (SD 110.9)	N: 25825 cataract procedures Median driving miles to closest CC facility: 8.7 (SD 21.7) Median driving miles to actual CC facility: 19.7 (SD 296.0)	N/A	<u>Stats:</u> drive distances generated with Geographic Information System (GIS) <u>Other methods of controlling:</u> N/A <u>Covariates:</u> N/A	Y	Reported national findings (there were additional state/regional data) and excluded heatmap data Considered mixed results because closest driving miles for CC was lower than that for VA but VA better in portion of comparisons (26% of CC)



Author Year Large Database (Y/N) Study Design Health Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
Augustine, 2018 ¹⁶ Y (National) Retrospective Kidney transplant	2004-2016, SRTR (vs other non-VA)	N: 2905 patients (no raw mortality, delisting event data) median distance transplant center (25%, 75%): 347.0 (196.9, 701.8)	N: 3751 (private) N: 3109 (Medicare) (no raw event data) median distance transplant center, private (25%, 75%): 42.5 (12.9, 101.1) median distance transplant center, Medicare (25%, 75%): 55.6 (16.4, 102.6)	VA vs private all transplants: HR(adj) 0.72 (95% CI: 0.65-0.79) VA vs private Mortality: HR(adj) 1.00 (95% CI: 0.83-1.20) VA vs private delisting: HR(adj) 1.23 (95% CI: 1.003-1.50) VA vs Medicare Mortality: HR(adj) 0.81 (95% CI: 0.68-0.96) VA vs Medicare delisting: HR(adj) 0.82; 95% CI, 0.68 to 0.99) unadjusted median distance: p<0.001	<u>Stats:</u> multivariable cox regression <u>Control:</u> matched VA with local non-VA centers in same DSA <u>Covariates:</u> age group, race, sex, diagnosis group, time on dialysis at listing, candidate status at listing, panel reactive antibody (PRA), body mass index group, education, malignancy, peripheral vascular disease, year of listing, region, log distance from candidate residence to listing center (distance in miles transformed on a log-10 scale), and community risk score	Y	surgeries took place further than the closest VA, for instance) Only reporting matched subset (another unmatched outcome set) Supplements were reviewed for raw event data - not included
Wu, 2018 ⁶³ Y (National) Retrospective Cataract	2002-2012 (vs other non-VA) VHA claims data vs medicare data	N: 1,917,254 patients Surgery within 1 y of cataract dx: 120,196 (6.3%) Surgery within 5 y of cataract diagnosis: 240,884 (12.6%)	N: 1,156,211 patients (Medicare) Surgery within 1 y of cataract dx: 213,589 (18.5%) Surgery within 5 y of cataract diagnosis: 414,586 (35.9%)	Surgery within 1 y of cataract dx: p<0.001; OR(adj): 3.39 (95% CI: 3.36-3.41) Surgery within 5 y of cataract dx: p<0.001; OR(adj): 3.89 (95% CI: 3.87-3.91) (Reference group: VHA)	<u>Stats:</u> multivariable logistic regression <u>Other methods of controlling:</u> N/A <u>Covariates:</u> age group, sex, race/ethnicity, region of US residence, Charlson Comorbidity Index score, systemic comorbidities, ocular comorbidities	Y	
Wagner, 2021 ⁶⁷ Y (National)	2017-2018 (vs vets in non-VA, "VA purchased") CDW	N: 6179 for inpatient TKAs and 65799 outpatient cataracts	N: 6337 for inpatient TKA and 5959 for outpatient cataracts	TKA: OLS regression coef=14869.2 (SE: 299.9), p<0.001	<u>Stats:</u> ordinary least squares <u>Other methods of</u>	Y	Only reported inpatient TKA



Author Year Large Database (Y/N) Study Design Health Condition Outcome Domains	Years of Source Data Comparison Group Data Source(s)	<u>VA Care:</u> N Outcomes (Raw Values)	<u>Non-VA Care:</u> N (Population) Outcomes (Raw Value)	Comparison Statistics Adjusted Model Findings	Statistical Method Other Methods of Controlling Covariates in Model	Bias Criteria Met?	Comments & Reason If Bias Criteria Not Met
Retrospective TKA and cataract		Average total cost of inpatient TKAs: \$28969 (SD \$10778) Average total cost of outpatient cataract surgeries: \$4301 (SD \$2835)	Average total cost of inpatient TKAs: \$13339 (SD \$23698) Average total cost of outpatient cataract surgeries: \$1585 (SD \$629)	Cataract: OLS regression coef=2680.0 (SE: 15.8), p<0.001 (Reference group: VA-purchased)	<u>controlling:</u> adjusted standard errors for clustering within person to account for the fact that people can have more than 1 cataract or TKA <u>Covariates:</u> age, gender, Nosos risk score, location of care (only for TKA analysis)		and outpatient cataract data
Mull, 2022 ⁶² Y (National) Retrospective Hernia repair	2018-2019 vs Veterans getting hernia repair through community care CDW	N: 7991 Unadjusted postoperative complications VA 4.0%, community care = 6.6%	N: 771 Unadjusted postoperative complication rate community care = 6%	Adjusted complication rate: no statistically significant difference	<u>Stats:</u> unadjusted – 2 sided t-tests, adjusted – 2-stage multivariable models <u>Covariates:</u> comorbidity, demographics, surgical complexity, historical referral rate	Y	



RISK OF BIAS ASSESSMENTS

NON-SURGICAL CARE

Trial Name or Author Year	Time Frames	Sample (VA and Non-VA)	How Did the Specifications for the Outcome Assessments Compare in VA and Non-VA Samples?	Statistical Methods
Nuti, 2016 ²⁷	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(ses)
Vanneman, 2020 ⁵⁰	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(ses)
Gurewich, 2021 ⁴⁷	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(ses)
Davila, 2021 ⁵¹	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(ses)
Intrator, 2021 ³⁰	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(ses)
LaBedz, 2021 ³⁸	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(ses)
Gidwani, 2021 ⁵³	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(ses)
Griffith, 2020 ⁴⁸	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(ses)
Gidwani-Marszowski, 2020 ⁴³	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(ses)
Penn, 2019 ⁴⁶	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(ses)

Trial Name or Author Year	Time Frames	Sample (VA and Non-VA)	How Did the Specifications for the Outcome Assessments Compare in VA and Non-VA Samples?	Statistical Methods
Makarov, 2018 ⁵²	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Wang, 2019 ³²	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Thorpe, 2018 ²⁸	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Vercammen-Grandjean, 2018 ³⁹	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Wang, 2018 ³³	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Augustine, 2018 ¹⁶	Contemporaneous time frames	All between A and C	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Anhang Price, 2018 ³⁷	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Kurella Tamura, 2018 ³⁴	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Barnett, 2018 ²⁶	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Heidenreich, 2017 ²¹	Contemporaneous time frames	All between A and C	Identical	All between A and C
Blay, 2017 ³⁶	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Mody, 2017 ²²	Contemporaneous time frames	All between A and C	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)

Trial Name or Author Year	Time Frames	Sample (VA and Non-VA)	How Did the Specifications for the Outcome Assessments Compare in VA and Non-VA Samples?	Statistical Methods
Shields, 2017 ²⁴	Contemporaneous time frames	All between A and C	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Burke, 2016 ¹⁷	Contemporaneous time frames	Small, limited, unequal or non-representative samples	Identical	Insufficient sample size and/or methods questionable to address hypothesis(es)
Lee, 2017 ¹⁸	Contemporaneous time frames	All between A and C	Identical	All between A and C
Axon, 2016 ²³	Contemporaneous time frames	All between A and C	Identical	All between A and C
Jia, 2016 ³¹	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Watkins, 2016 ⁴⁰	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Jones, 2015 ¹⁴	Contemporaneous time frames	All between A and C	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Chan, 2022 ⁴²	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Florez, 2021 ¹⁵	Contemporaneous time frames	All between A and C	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Feyman, 2022 ⁴⁹	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Cashion, 2021 ³⁵	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Presley, 2022 ²⁵	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	All between A and C
Pickering, 2022 ⁵⁴	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)

Trial Name or Author Year	Time Frames	Sample (VA and Non-VA)	How Did the Specifications for the Outcome Assessments Compare in VA and Non-VA Samples?	Statistical Methods
Fortney, 2022 ¹⁹	Contemporaneous time frames	All between A and C	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Scheuner, 2022 ⁴⁴	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Petros, 2022 ²⁰	Contemporaneous time frames	All between A and C	Identical	All between A and C
Ramanathan, 2023	Contemporaneous time frames	All between A and C	Identical	All between A and C
Gaffney, 2022	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	All between A and C
Weeda, 2023	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Ohl, 2023	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Yoon 2023	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Sufficiently similar for valid comparisons	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Wachterman 2023	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	All between A and C
Wadhwa 2024	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Sufficiently similar for valid comparisons	Sufficient sample size and/or methods appropriate to address hypothesis(es)



SURGICAL CARE

Trial Name or Author Year	Time Frames	Sample (VA and Non-VA)	How Did the Specifications for the Outcome Assessments Compare in VA and Non-VA Samples?	Statistical Methods
Buyts 2024	Contemporaneous time frames	Small, limited, unequal or non-representative samples	Sufficiently similar for valid comparisons	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Simmonds 2023	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Yoon 2023	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Sufficiently similar for valid comparisons	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Harris, 2021 ⁶⁹	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Petty, 2021 ⁶⁵	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Rosen, 2021 ⁵⁶	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Wagner, 2021 ⁶⁷	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Sufficiently similar for valid comparison	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Heiden, 2021 ⁶⁸	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Sufficiently similar for valid comparison	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Billig, 2021 ⁶⁴	Contemporaneous time frames	Small, limited, unequal or non-representative samples	Identical	All between A and C
Griffith, 2020 ⁴⁸	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Kesseli, 2020 ⁶¹	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)



Trial Name or Author Year	Time Frames	Sample (VA and Non-VA)	How Did the Specifications for the Outcome Assessments Compare in VA and Non-VA Samples?	Statistical Methods
Rosen, 2020 ⁷⁰	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Eid, 2020 ⁶⁶	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Frisch, 2020 ⁵⁷	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Williams, 2020 ⁶⁰	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Augustine, 2018 ¹⁶	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Wu, 2018 ⁶³	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Barnett, 2018 ²⁶	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Sufficiently similar for valid comparison	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Blay, 2017 ³⁶	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Hutt, 2015 ⁵⁹	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Sufficiently similar for valid comparison	Sufficient sample size and/or methods appropriate to address hypothesis(es)
George, 2021 ⁶	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Sufficiently similar for valid comparison	Sufficient sample size and/or methods appropriate to address hypothesis(es)
George 2024	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Sufficiently similar for valid comparisons	Sufficient sample size and/or methods appropriate to address hypothesis(es)
Mull, 2022 ⁶²	Contemporaneous time frames	Representative or national samples (both VA and non-VA)	Identical	Sufficient sample size and/or methods appropriate to address hypothesis(es)



PEER REVIEW COMMENTS AND RESPONSES

Comment #	Reviewer #	Comment	Author Response
<i>Are the objectives, scope, and methods for this review clearly described?</i>			
1	1	Yes	Thank you.
2	2	Yes	Thank you.
3	3	Yes	Thank you.
4	4	Yes	Thank you.
5	5	Yes	Thank you.
6	7	Yes	Thank you.
7	8	Yes	Thank you.
8	10	Yes	Thank you.
<i>Is there any indication of bias in our synthesis of the evidence?</i>			
9	1	No	Thank you.
10	2	No	Thank you.
11	3	No	Thank you.
12	4	No	Thank you.
13	5	No	Thank you.
14	7	No	Thank you.
15	8	No	Thank you.
16	10	No	Thank you.
<i>Are there any published or unpublished studies that we may have overlooked?</i>			
17	1	No	Thank you.
18	2	No	Thank you.
19	3	No	Thank you.
20	4	No	Thank you.
21	5	Yes - Recent JAMA Open Network paper on wait times in VA and Community Care by Feyman et al.	This has been added to the report and map.
22	7	No	Thank you.

Comment #	Reviewer #	Comment	Author Response
23	8	No	Thank you.
24	10	No	Thank you.
<i>Additional suggestions or comments can be provided below.</i>			
25	1	Overall this is an excellent review of the literature comparing VA to non VA care. The authors have divided the available studies into surgical and non surgical care, and divided the outcomes according to standard health services research categories. I was particularly glad to see that more studies are now available outside of quality and safety. The summary figure is very useful and will no doubt be very informative to policy makers.	Thank you for your comment.
26	1	The search methods were quite thorough and I have little doubt that they have found all the relevant published literature. The inclusion criteria are very reasonable. I have some curiosity about whether the few excluded lower quality (fatal flaw) studies tended in the same direction of equal or better VA care overall, but in the end I think it is probably better that the authors did not spend time in sensitivity analyses in that direction.	We have now added information about these fatal flaw studies.
27	1	Most of my suggestions revolve around interpretation. I would give more valence to more recent studies as the both the VA and non VA system are evolving over time. The last paragraph of the discussion covers the difference between the pre2015 and post2015 studies. I would have liked a bit more detail those differences.	We have now called out in each text section those studies specifically about the CHOICE/MISSION act comparisons, which are most of the more recent studies, and the comparison of greatest policy interest.
28	1	Similarly there were innovative recent studies that probably deserve more highlighting. Observational studies are of course always subject to bias, and the authors do a great job of assessing how robust the individual studies are. However the recent Chan study on mortality was	Unfortunately the Chan study was the only one of its kind. We have beefed up and discussed in more detail that the #1 limitation to all studies is the possibility of unmeasured confounding. I don't think we can do better than that.

Comment #	Reviewer #	Comment	Author Response
		particularly interesting in that it used a novel instrumental variable and was directed at a particularly important outcome - mortality. There were only a handful of other mortality studies in either surgical or nonsurgical care, and by the description provided all of narrower scope or poorer quality. I would have like to see a paragraph or at least a statement on how this key outcome compared.	
29	1	Finally it is important to note that almost all the studies covered only a single or small subset of conditions. Thus the overall conclusion about VA care could be limited to those conditions and that might be noted.	This has been added to the Limitations.
30	2	Well conducted review. Limitation of what's available is noteworthy. Looking at the surgical topics, the specialty areas are focused on specific operations/diseases eg. lung resection for NSC; or kidney transplant. These clearly are important, but are probably not the common bread/butter operations that all the VA surgical care address.	This has been added to the Limitations.
31	3	An obvious limitation is that the data do not provide insights on social challenges of veteran patients that are exacerbated by receiving care in a VHA facility that can influence hospital length of stay following surgery (e.g. availability of family/friend to take home when meeting discharge criteria).	This has been added to the Limitations.
32	4	Page 14, lines 20-21. One of the main impetus for carrying out this evidence synthesis was to evaluate the quality of care Veterans receive in the community following passage of the Choice (2014) and MISSION (2018) Acts. And the authors were tasked with categorizing studies based on whether Veterans received care at a VA facility as opposed to a community facility through the Choice and MISSION Acts. However, a lot of the studies included in this summary had	<p>We have now separated out in the map and the text the studies that are about non-VA care received as part of the CHOICE or MISSION Act.</p> <p>Given that we identified some studies that compared VA care to VA-paid community care that preceded the CHOICE Act, we grouped all of these into a category now called "compared to Veterans getting VA-paid community care"</p>

Comment #	Reviewer #	Comment	Author Response
		analyzed data that pre-dated the Choice and MISSION Acts. It would be nice to have some delineation or header in the manuscript for studies that specifically analyzed data after passage of the Choice legislation starting in 2014/2015.	
33	4	Page 15, line 24: Was 'Timing' defined by publication date or when data was collected. As mentioned above, it appears that a lot of data included in this evidence synthesis was collected prior to 2015.	Timing was publication date as this update was intended to pick up the evidence where the last systematic review stopped.
34	4	Page 21, line 60. I was wondering why cardiovascular revascularization procedures were included in KQ#1 group as opposed to KQ#2. It might make more sense to group all interventional procedures in the surgical group.	We agree that this is one potential classification system, but elected to keep the organization consistent with the prior 2012 review, which classified studies into surgery vs non-surgery (medical).
35	4	Page 24, line 45: There is a typo; delete "for".	This has been fixed, thank you.
36	4	Page 27, line 46: I am curious why the authors included "Hospital Patient Safety Indicators and Outpatient Quality of Care" studies under the Patient Experience heading. It seems out of place.	This paragraph about these two studies was inadvertently placed in Patient Experience. It has now been moved to where it belongs in Quality and Safety.
37	5	In general, this is a succinct, clearly written report. The organization is clear, the methods seem appropriate and the conclusions generally sound. I have inserted a number of comments directly in the report but have 4 general observations/suggestions:	Thank you for your comments.
38	5	1. The report describes two general types of studies: comparisons restricted to Veterans getting care in VA or non-VA setting, and comparisons of VA outcomes to general population outcomes. In fact there are further differences. In the first category, there are studies comparing enrolled veterans who get care in VA	We have now split out the studies of comparison to CHOICE/MISSION Act care.

Comment #	Reviewer #	Comment	Author Response
39	5	<p>or VA-paid care provided outside VA through Community Care/choice/contracted care. There are also studies comparing outcomes of dually eligible veterans who get care in VA vs in Medicare. Among the second group of studies, there are studies where comparison population are all insured (Medicare, Medicaid or HMO comparisons) and others where the population comparisons are non-VA hospital patients who include a mix of insured and uninsured.</p> <p>2. The report gives insufficient attention to the challenges in comparing quality and outcomes based on available data and how various sources of bias will vary based on the populations being compared and the outcomes used. I would have preferred more comment on the adequacy of efforts to control for clinical factors – if this was part of the evaluation of methods in the bias assessment it should be stated more clearly. The ability to adequately control for clinical and sociodemographic factors that affect clinical outcomes like mortality and readmission will vary substantially if some of the records are Medicare or private health systems. The cleanest comparisons are those that use Veteran populations and compare care in VA to that bought outside VA for the same patients, since both populations are insured, have comparable data, and are using the VA. For studies comparing enrolled Veterans getting VA care vs Medicare, there are selection factors that lead to greater VA or greater Medicare use that can bias outcomes. For some outcomes, claims level data may be adequate but for others such as CHF and MI, severity may vary by the source of care. Perhaps this is less than an issue than I worry, but some discussion should be included about what we know about the severity of illness and comorbidity of Veterans who get care in VA and those who get care in Medicare, or of Veterans</p>	<p>The issue of comparability has been added to the Limitations.</p>

Comment #	Reviewer #	Comment	Author Response
		vs. general Medicare population. Similarly, comparing VA hospital outcomes to private hospitals will be affected by the comorbidity of patient populations and sociodemographics. Readmissions may be driven by patients who are uninsured with poor social supports.	
40	5	3. Table D on the medical care studies is confusing and spars in the data. Table E is much better organized and it would be preferable that Table D be reformatted in that manner. At a minimum, better description of the PICOTs elements for each study should be included at the beginning before listing all the individual outcome comparisons.	This has been reformatted.
41	5	4. The conclusions should spend a little more time in discussing the potential uses of this data and which comparisons might be most useful. First, comparisons are useful in identifying possible quality issues where VA performance should be improved. Looking at specific outcomes is important. Second, comparisons of VA vs Community Care are critical to shaping decisions about the expansion of that program and determining whether sending Veterans out for care in an effort to improve timeliness or convenience comes as a cost in terms of clinical outcomes. Third, some comparisons are useful at judging the potential advantages of the VA's national system of integrated care vs. care delivery in less organized settings – eg delivery of preventive care and control of chronic disease.	This has been added to the Discussion.
42	5	5. Recommendations for research are underdeveloped.	This has been fixed.
43	5	Page 16, Line 11: What about studies ability to adjust for differences in patient population -- eg underlying health status? If you didnt include this perhaps state why.	Adjusting for differences in patient population was one of the factors considered in “appropriate statistical methods”. We have added this to the text.

Comment #	Reviewer #	Comment	Author Response
44	5	Literature Flow: Is it meant to be "...Clinical Care in VA..."	This has been fixed.
45	5	Literature Flow: Same error here: ...Quality of clinical CARE...	This has been fixed.
46	5	Page 22, Line 46: Did this study adjust for HF severity?	This study was not able to adjust for HF severity, only for the presence or absence of multiple comorbidities. We added this information to the text, and noted in the Limitations that the inability to control for things like this is a problem.
47	5	Page 23, Line 11: The nursing home populations are very different in VA and non-VA settings, especially by gender, age and presence of dementia. The ability to adjust for these differences will depend on the outcome being assessed.	We have added to the text the variables that were used in adjustments.
48	5	Page 23, Line 31: What risk factors were adjusted for?	We have added to the text the variables that were used in adjustments.
49	5	Page 23, Line 51: This sentence is potentially confusing -- I assume that is is a hazard ratio from a time-dependent model, but the point that it implies lower rates of transplant may be lost. I would clarify with a parenthetical phrase (lower rate of transplant)	We added this parenthetical phrase.
50	5	Page 26, Line 40: Better?	We changed 'higher' to 'better'.
51	5	Page 26, Line 56: Is timing to transplant affected by the organ allocation system that VA does not control?	We do not know the answer to this question and the article itself does not provide information about this.
52	5	Page 28, Line 4: Risk adjusted readmission?	Yes these are risk-adjusted and we have added that to the text.
53	5	Page 36, Line 35: Length of stay in VA can be driven by problems with nursing home placements. While this is a relevant indication of a problem it is different than if it were due to other factors.	This is acknowledged but nevertheless, the data are what they are and are compatible with the experience of VA clinicians on the inpatient service: length of stay is much longer in VA due to disposition challenges.
54	5	Page 36, Line 60: I think more needs to be said about the ability of individual studies to account	This has been added to the Limitations.

Comment #	Reviewer #	Comment	Author Response
		for differences in study populations, differences in who seeks community care, etc. These differences paly out differently depending on study design and outcome. A study of CHF mortality that cant adjust for severity of CHF is prone to error. Can we say anything about the underlying comorbidity of VA vs, medicare patients?	
55	7	None	
56	8	This report is flawless from a standpoint of rigor and analysis. It is, however, a bit dense for busy policymakers. The bubble charts (a nice innovation) help but take a bit of time to absorb. I suggest 2 minor enhancements:	Thank you for your comment.
57	8	1. Include a "Pull Out Box" that quickly states what this new report adds. (I note that BMJ, Annals, MMWR have recently instituted these so check them out if you want to see what I'm talking about)	We think the "Key Findings" box at the beginning of the Executive Summary does this.
58	8	2. To make the bubble charts easier to use, start with a set of instructions first (right now, the key is a footnote to the chart) that orient the user. (This may take a bit of trial and error and perhaps a willing "test audience")	This set of instructions is contained in the text.
59	10	This evidence synthesis report updates prior comparisons of the quality of VA and non-VA care to include those published between 2015 to 2021. The comparisons were grouped under the broad category of non-surgical and surgical care - again in line with previously published evaluations. The search strategy appeared comprehensive and the studies were graded in a rigorous manner. I think this was a well-done synthesis.	Thank you for your comment.
60	10	Main suggestions: 1) One of the key conclusions is as follows: "In the domain of quality and safety, the great majority of studies found that VA care is as good as, or better than, care in the	We considered adding this....but ultimately elected not to do so, because it may make casual readers assume

Comment #	Reviewer #	Comment	Author Response
		<p>community." While this is a reasonable summary, I view "better than" to be fundamentally distinct from "as good as". I would consider whether this distinction should be made in the abstract/executive summary. Ie, XXX studies demonstrated the VA was better than, YYY studies showed the VA was as good as , and ZZZ studies showed the VA delivered worse ..."</p> <p>This grouping would align better with the evidence maps that bucketed studies into the following groupings: "VA care is better", "VA and community have equal or mixed results", and "community care is better".</p>	<p>that we – the authors – are giving equal weight to each study, which we aren't doing.</p>
61	10	<p>2) Although there was a lot of appropriate description of the validity of the studies and grading the quality of the research among a number of dimensions. I wonder if the research team included the importance of the outcome or quality measure in its assessment. In other words, some measures - like mortality and patient ratings of care - have strong face validity as important indicators of quality. For others - like length of stay and costs, it is not clear whether these actually represent quality measures (vs undefined metrics of resource utilization), whether lower is necessarily better, or whether they are appropriately risk-adjusted - particularly for critical factors like social support, function, or availability of stable housing.</p>	<p>This is a great question and one we discussed extensively. The problem is that if we, the research team, picks "importance" it is necessarily a subjective assessment. While at the extremes this may not be controversial—the example given of mortality compared to length of stay—other distinctions might be more controversial: for example, which is more important? Wait times for a urology appointment versus length-of-stay following joint replacement surgery? Because we did not think we could draw a bright and defensible line between important and less important outcomes, we elected to put them all in without an "importance" qualifier. But we did add to the Limitations that some outcomes will be more important than others and that this may vary by stakeholder.</p>
62	10	<p>3) There were five studies excluded because of "fatal flaws". Would consider adding a brief description of the fatal flaw to exhibit B - similar to what was done in Exhibit C to describe why each studies did not meet inclusion criteria.</p>	<p>This was probably a bad use of jargon on our part. We have re-named them for what they are: unrepresentative samples, most single provider or single site studies.</p>
63	10	<p>4) It is unclear why studies of travel distance were included in this review. Longer travel distances for Veterans receiving some kinds of care (ie transplant) compared to non-Veterans may relate to decisions about whether VA</p>	<p>Travel distance was included in the review because it was in CHOICE as a criterion. We have added to the Limitations that travel distance may be of differing importance to different stakeholders.</p>



Comment #	Reviewer #	Comment	Author Response
64	10	<p>patients are more likely to live in rural locations and the fact that the VA serves a subset of military veterans in ~130 centers whereas community care by definition includes the entire US population and all clinical facilities.</p> <p>5) In grading the quality of the evidence, did the authors consider the appropriateness of the risk-adjustment models? Many of the studies that examine mortality and readmission rely on claims-based approaches and compare outcome in the VA with that in Medicare. Given the incentives for private providers to overcode comorbidities, this kind of approach may penalize the VA since Medicare or private-sector patients would be labeled as being sicker. If some comparisons include a more comprehensive (and less "gameable") set of risk-adjustment variables, perhaps they should be called out as being stronger.</p>	<p>This is a great comment and something we tried to assess but have added to the limitations that for some it is impossible (like the upcoding in FFS medicine).</p>